

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



B2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/20634</b> <b>(43) International Publication Date:</b> 13 April 2000 (13.04.00)
<b>(21) International Application Number:</b> PCT/IB99/01696 <b>(22) International Filing Date:</b> 1 October 1999 (01.10.99)  <b>(30) Priority Data:</b> 60/102,624 1 October 1998 (01.10.98) US  <b>(71) Applicant:</b> NOVA MOLECULAR, INC. [CA/CA]; Suite 105, 5252 de Maisonneuve West, Montreal, Quebec H4A 3S5 (CA).  <b>(72) Inventor:</b> SCHAPPERT, Keith; Apartment 607, 3600 Parc Avenue, Montreal, Quebec H2X 3R2 (CA).  <b>(74) Agent:</b> MBM & CO.; P.O. Box 809, Station B, Ottawa, Ontario K1P 5P9 (CA).		<b>(81) Designated States:</b> AU, CA, JP, MX, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> METHODS FOR TREATING OR IDENTIFYING A SUBJECT AT RISK FOR A NEUROLOGICAL DISEASE BY DETERMINING THE PRESENCE OF A VARIANT GPIIIA AND/OR VARIANT GPIIB ALLELE  <b>(57) Abstract</b>  The invention provides methods for treating or identifying subjects having a neurological disease or at risk for a neurological disease by determining the presence of a variant GPIIIa and/or GPIIb allele.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5     METHODS FOR TREATING OR IDENTIFYING A SUBJECT AT RISK FOR A  
      NEUROLOGICAL DISEASE BY DETERMINING THE PRESENCE OF A  
      VARIANT GPIIIA AND/OR VARIANT GPIIB ALLELE

10                   Background of the Invention

      In general, the invention relates to methods for treating a neurological disease.

      Neurological diseases, for example, Alzheimer's disease, are often difficult to  
diagnose and occur in the population in a manner which is difficult to predict. A  
method that would allow one to identify subjects having a neurological disease, or  
15     being at risk for developing a neurological disease, would allow for the more timely  
administration of an appropriate therapy.

      The GPIIIa gene encodes a 788 amino acid polypeptide with a 26-residue  
signal peptide, a 29-residue transmembrane domain near the carboxy terminus, and  
four cysteine-rich domains of 33-38 residues each (Zimrin et al., *J. Clin. Invest.*  
20     81:1470-1475 (1988)). Two different antigenic forms of GPIIIa, alloantigens PlA1  
and PlA2 (for Platelet Antigen 1 and 2), have been described and can be distinguished  
using a monoclonal antibody (Weiss et al., *Tissue Antigens* 46:374-381 (1995)). The  
most predominant form of GPIIIa, PlA1, is carried by 98% of the Caucasian  
population. The rarer form of GPIIIa, PlA2, has sustained a point mutation at base  
25     192 that causes a nucleotide change from a T to a C and thus a leucine to proline  
(CTG > CCG) amino acid substitution at residue position 33 (Newman et al., *J. Clin.*  
*Invest.* 83:1778-1781 (1989)).

      The GPIIb polypeptide is the larger component of the GPIIIa/GPIIb complex  
and comprises two disulfide-linked subunits of 137 amino acids and 871 amino acids  
30     each. The larger GPIIb polypeptide has a 26 amino acid signal sequence, a potential  
transmembrane domain, and four stretches of 12 amino acids each that are  
homologous to the calcium binding sites of calmodulin and troponin C (Poncz et al., *J.*  
*Biol. Chem.* 262(18):8476-8482 (1987)). Mutational analysis of these domains has  
indicated that these calcium-binding domains are required for the correct folding and

transport of the GPIIb polypeptide to the cell surface (Basani et al., *Blood* 88:167-173 (1996)). Two antigenic forms of GPIIb, Bak<sup>a</sup> and Bak<sup>b</sup>, have been described and can be distinguished using specific antisera. The less common form of GPIIb (i.e., Bak<sup>b</sup>) was determined to have a T to G point mutation that results in an isoleucine to serine substitution at amino acid position 843 (Lyman et al., *Blood* 75:2343-2348 (1990)).

### Summary of the Invention

The present invention provides methods for identifying or treating a subject at risk for, or diagnosed with, a neurological disease.

In the first aspect, the invention provides a method for identifying a subject at risk for a neurological disease by: identifying the subject; determining the genotype or phenotype of the GPIIIa or GPIIb locus of the subject; and determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform, where the presence of the variant GPIIIa allele or isoform or the variant GPIIb allele or isoform is indicative of the subject having an increased risk of the neurological disease. Preferably, the neurological disease is Alzheimer's Disease (AD).

In the second aspect, the invention provides a method for diagnosing a subject with a neurological disease by: identifying the subject; determining the genotype or phenotype of the GPIIIa or GPIIb locus of the subject; and determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform, where the presence of the variant GPIIIa allele or isoform or the variant GPIIb allele or isoform is indicative of the subject having a likelihood of the neurological disease.

In the third aspect, the invention provides a method for characterizing the genotype of at least one subject involved in a clinical trial of a therapy for the treatment of a neurological disease by: identifying the subject; determining the genotype or phenotype of the GPIIIa or GPIIb locus of the subject before, during, or after the clinical trial; and determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform, where the presence of the variant GPIIIa allele or isoform or the variant GPIIb allele or isoform places the subject into a subgroup for the clinical

trial. Preferably, the genotype or phenotype is indexed against the efficacy or side-effects of the therapy.

In the fourth aspect, the invention provides a method for treating a subject with a neurological disease by: identifying the subject; determining the genotype or  
5 phenotype of the GPIIIa or GPIIb locus of the subject; determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform; and determining the preferred therapy for the treatment of the neurological disease.

In the fifth aspect, the invention provides a method for treating a subject at risk for a neurological disease by: identifying the subject; determining the genotype or  
10 phenotype of the GPIIIa or GPIIb locus of the subject; determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform; determining the GPIIIa or GPIIb allele status of the subject, where the allele status is predictive of patient outcome or drug efficacy.

In a preferred embodiment of the above aspects, the method includes  
15 determining the presence of both the variant GPIIIa allele or isoform and the variant GPIIb allele or isoform.

In other preferred embodiments of the above aspects, the neurological disease may be Alzheimer's disease (AD), a non-AD neurological disease, or a neurological disease selected from the group consisting of Alzheimer's disease, neurofibromatosis,  
20 Huntington's disease, depression, amyotrophic lateral sclerosis, multiple sclerosis, stroke, Parkinson's disease, and multi-infarct dementia.

In other preferred embodiments of the above aspects, the determining may be performed using a nucleic acid that specifically binds a nucleic acid encoded by the variant GPIIIa allele or the variant GPIIb allele. In other preferred embodiments of  
25 the above aspects, the determining may be performed using an antibody that specifically binds a polypeptide encoded by the variant GPIIIa allele or the variant GPIIb allele, but does not bind a polypeptide encoded by a wild-type GPIIIa allele or a wild-type GPIIb allele.

In other preferred embodiments of the above aspects, the variant GPIIIa allele

may have a point mutation at nucleotide base 192 of SEQ ID NO: 2 or encode a polypeptide with a proline at amino acid position 33 of SEQ ID NO: 4. In other preferred embodiments of the above aspects, the variant GPIIb allele may have a point mutation at nucleotide base 2622 of SEQ ID NO: 6 or encode a polypeptide with a serine at amino acid position 843 of SEQ ID NO: 8.

The presence of a variant allele may be determined by genotyping nucleic acids from the subject or by assaying for the presence of a protein having alterations encoded by the variant nucleic acid.

By "neurological disease" is meant a disease, which involves the neuronal cells of the nervous system. Specifically included are: prion diseases (e.g., Creutzfeldt-Jakob disease); pathologies of the developing brain (e.g., congenital defects in amino acid metabolism, such as argininosuccinicaciduria, cystathioninuria, histidinemia, homocystinuria, hyperammonemia, phenylketonuria, tyrosinemia, and fragile X syndrome); pathologies of the mature brain (e.g., neurofibromatosis, Huntington's disease, depression, amyotrophic lateral sclerosis, multiple sclerosis); conditions that strike in adulthood (e.g. Alzheimer's disease, Creutzfeldt-Jakob disease, Lewy body disease, Parkinson's disease, Pick's disease); and other pathologies of the brain (e.g., brain mishaps, brain injury, coma, infections by various agents, dietary deficiencies, stroke, multiple infarct dementia, and cardiovascular accidents).

By "cognitive enhancers" is meant drugs which enhance a) memory performance, whether it is verbal memory, spatial memory, or factual memory and b) learning capacity.

By "cholinomimetic therapy" is meant any drug that mimics the function of acetylcholine or enhances the activity of acetylcholine synthesizing cells. These drugs include, but are not limited to, inhibitors of acetylcholine degradation (acetylcholine esterase inhibitors such as tacrine), drugs that mimic acetylcholine structure and function, drugs that block acetylcholine uptake by neurons, and drugs that interact with pre-synaptic receptors to induce acetylcholine release from cholinergic neurons.

By "non-cholinomimetic vasopressinergic therapy" is meant a therapy that

utilizes a vasopressinergic modulator such as, for example, S12024 (provided by Servier, Les Laboratoires Servier, 22 rue Garnier, 92200 Neuilly sur Seine, France).

By "already diagnosed" is meant already diagnosed as having the neurological disease, having a genetic predisposition to the disease, or both.

5 By "patient profile" is meant data pertaining to the patient for whom the pharmacogenetic analysis is being performed. Data may include information on the patient's diagnosis, age, sex, and genotype. The patient's profile may also include materials from the patient such as blood or purified RNA or DNA.

10 By "prognosis protocol" is meant a therapy plan provided to the clinician or patient using the pharmacogenetic method. The prognosis protocol includes an indication of whether or not the patient is likely to respond positively to a cholinomimetic therapeutic. In preferred embodiments, the protocol also includes an indication of the drug dose to which the patient is most likely to respond. The "pharmacogenetic method" is a method whereby genetic and diagnostic data,  
15 including the patient's neurological diagnosis and the patient's GPIIIa and/or GPIIb genotype are processed to provide therapeutic options and prognoses.

By "non-AD neurological disease" is meant a disease other than Alzheimer's disease, which involves the neuronal cells of the nervous system. Specifically included are: prion diseases (e.g., Creutzfeldt-Jakob disease); pathologies of the  
20 developing brain (e.g., congenital defects in amino acid metabolism, such as argininosuccinicaciduria, cystathioninuria, histidinemia, homocystinuria, hyperammonemia, phenylketonuria, tyrosinemia, and fragile X syndrome); pathologies of the mature brain (e.g., neurofibromatosis, Huntington's disease, depression, amyotrophic lateral sclerosis, multiple sclerosis); conditions that strike in  
25 adulthood (e.g. Creutzfeldt-Jakob disease, Lewy body disease, Parkinson's disease, Pick's disease); and other pathologies of the brain (e.g., brain mishaps, brain injury, coma, infections by various agents, dietary deficiencies, stroke, multi-infarct dementia, and cardiovascular accidents).

By "Alzheimer's Disease" is meant a pathology characterized by an early and

extensive loss of entorhinal cortex neurons. Alzheimer's disease subjects may be identified by progressive and degenerative effects on the brain which are not attributable to other causes. A diagnosis of Alzheimer's disease is made using clinical-neuropathological correlations known in the art (see e.g., *Arch. Neurology* 51(9):888-896 (1994)). Post-mortem, the disease may be diagnosed by the presence of amyloid plaques and fibrils.

As used herein, by "therapy for the treatment of a neurological disease" is meant any therapy suitable for treating a neurological disease. A suitable therapy can be a pharmacological agent or drug that may enhance or slow the loss of cognitive function, motor function, or neuronal activity of the central nervous system, peripheral nervous system, or inhibit the further deterioration of any of these faculties. In addition, the term therapy may also include the close monitoring of an asymptomatic patient for the appearance of any symptoms of a neurological disease.

By "determining the presence of a variant GPIIIa and/or variant GPIIb allele" is meant subjecting a nucleic acid sample to any of a variety of detection techniques known in the art for elucidating a point mutation in a nucleic acid (e.g., polymerase chain reaction (PCR), reverse transcriptase-PCR (RT-PCR), ligase-mediated chain reaction step, chip hybridization methods, or restriction enzyme-mediated digestion). For example, in the presence of appropriately designed primers, a nucleic acid fragment can be amplified using PCR and analyzed by restriction enzyme digestion that can reveal the presence of a variant allelic sequence. In addition, DNA sequencing may be employed using techniques known in the art. These nucleic acid techniques allow for a genotype determination of the GPIIIa or GPIIb locus. Alternatively, phenotyping of the locus may be performed (and a genotype thus inferred) by using standard techniques for detecting the presence of a polypeptide having a particular amino acid change (e.g., antibodies, isoelectric focusing, and 2-D PAGE). For example, the presence of a variant GPIIIa polypeptide (e.g., PLA2; LEU33PRO) can be distinguish from a wild-type GPIIIa polypeptide (i.e., PLA1) using epitope specific antibodies available in the art (Weiss et al., *Tissue Antigens* 46:374-



381 (1995)). Antibodies for detecting different polymorphisms of the GPIIb polypeptide have also been described (Lyman et al., *Blood* 75:2343-2348 (1990)).

By "variant GPIIIa allele" is meant any sequence mutation of the glycoprotein integrin beta-3 subunit (GPIIIa) gene, that differs from the predominant wild-type allelic sequence (e.g., variant GPIIIa allele (LEU33PRO)) and which is associated with neurological disease. By "associated" is meant associated with an altered risk of disease incidence, drug efficacy, or disease prognosis. Variant GPIIIa allele not specifically described to be associated with neurological disease herein can be tested for association using the techniques provided herein and those known in the art specifically excluded are GPIIIa variants that have an A>C mutation at nucleotide base 1159, and A>G mutation at nucleotide base 1549, or a G>C mutation at nucleotide base 1161.

By "variant GPIIb allele" is meant any sequence mutation of the glycoprotein integrin alpha-2 subunit (GPIIb) gene that differs from the predominant wild-type allelic sequence (e.g., variant GPIIb allele (ILE843SER)) and which is associated with neurological disease. By "associated" is meant associated with an altered risk of disease incidence, drug efficacy, or disease prognosis. Variant GPIIb allele not specifically described to be associated with neurological disease herein can be tested for association using the techniques provided herein and those known in the art specifically excluded are GPIIIa variants that have an A>C mutation at nucleotide base 1159, and A>G mutation at nucleotide base 1549, or a G>C mutation at nucleotide base 1161.

By "risk factor associated with a disease" is meant any risk factor for a disease known in the art. Examples of risk factors commonly associated with diseases include age, gender, diet, exercise, weight, the presence of another disease, and the occurrence of a specific genotype. Risk factors associated with a neurological disease in particular may include advanced age, lower intelligence, smaller head size, history of head trauma, mutations on chromosomes 1, 14, and 21, or the presence of a variant GPIIIa and/or variant GPIIb allele (see e.g., Cummings et al., *Neurology* (1

Supp.1):S2-S17, 1998).

By "subject at risk for a neurological disease" is meant a subject identified or diagnosed as having a neurological disease or having a genetic predisposition or risk for acquiring a neurological disease using the methods of the invention and techniques available to those skilled in the art.

By "wild-type" is meant any allele, or polypeptide encoded by such an allele, that is present in that part of the population considered free of disease.

By "PCR, RT-PCR, or ligase chain reaction amplification" is meant subjecting a DNA sample to a Polymerase Chain Reaction step or ligase-mediated chain reaction step, or RNA to a RT-PCR step, such that, in the presence of appropriately designed primers, a nucleic acid fragment is synthesized or fails to be synthesized, thereby revealing the allele status of a patient. The nucleic acid may be further analyzed by DNA sequencing using techniques known in the art.

The present invention provides a number of advantages. For example, the methods described herein allow for a determination of a subject's GPIIIa and/or GPIIb genotype for the timely administration of a prophylactic therapy for the treatment of a neurological disease.

Other features and advantages of the invention will be apparent from the following detailed description and from the claims.

#### Detailed Description of the Invention

The drawings will first be described.

#### Brief Description of the Drawings

Fig. 1 is a depiction of the cDNA sequence encoding the wild type human GPIIIa polypeptide (SEQ ID NO: 1).

Fig. 2 is a depiction of the cDNA sequence encoding the variant human GPIIIa polypeptide (SEQ ID NO: 2) which has a nucleotide point mutation at base 192. The

T to C point mutation creates a new Msp I restriction site (          ) and results in a codon that encodes a proline at position 33 (indicated in bold and offset by spaces).

Fig. 3 is a depiction of the amino acid sequence of the wild type human GPIIIa polypeptide (SEQ ID NO: 3). The 26 amino acid signal sequence is underlined and the wild type leucine residue at position 33 is indicated in bold.

Fig. 4 is a depiction of the amino acid sequence of the human GPIIIa polypeptide (SEQ ID NO: 4) with a single amino acid residue change, from an leucine (L) to a proline (P) at position 33, indicated in bold. The 26 amino acid signal sequence is underlined.

Fig. 5 is a depiction of the cDNA sequence encoding the wild-type human GPIIb polypeptide (SEQ ID NO: 5). The codon encoding the wild-type isoleucine residue at position 843 is indicated in bold.

Fig. 6 represents the cDNA sequence encoding the variant human glycoprotein IIB polypeptide (SEQ ID NO: 6) which has a point mutation (T to G) at nucleotide base 2622. The point mutation creates a new Hae II restriction site (          ) and a codon (indicated in bold and offset by spaces) that encodes a serine at position 843.

Fig. 7 shows the amino acid sequence of the wild-type human glycoprotein IIB polypeptide (SEQ ID NO: 7). The wild-type isoleucine residue at position 843 is indicated in bold.

Fig. 8 shows the amino acid sequence of the variant human glycoprotein IIB polypeptide (SEQ ID NO: 8). The single amino acid residue change, from an isoleucine (I) to a serine (S) at position 843, is indicated in bold.

The invention described herein features methods for treating or identifying a subject at risk for a neurological disease, such as Alzheimer's disease (AD), by determining the presence of a variant GPIIIa or variant GPIIb allele. The invention also provides a method for forecasting patient outcome and the suitability of the patient for entering a clinical drug trial for the testing of a therapy for a neurological disease.

Normally, these alleles encode glycoproteins IIIa and IIb of the GPIIIa/GPIIb complex that belongs to a class of multi-subunit integrin receptors that bind cell adhesion molecules. These receptors are composed of alpha and beta subunits referred to, counter intuitively, as GPIIb and GPIIIa, respectively. Together, the GPIIIa beta and GPIIb alpha subunits form part of the platelet complex receptor, fibronectin receptor, and vitronectin receptor, and play a role in clotting. As expected, these polypeptides are expressed in platelets and endothelial cells (Hynes et al., *Cell* 48: 549-554 (1987)).

We have discovered that GPIIb and GPIIIa alleles are associated with the occurrence of neurological disease. For example, the presence of a particular variant GPIIIa allele that results in a single amino acid change from a leucine to a proline at residue 33 (LEU33PRO) indicates, with a high probability, that a subject is at risk for a neurological disease such as Alzheimer's disease (AD). In addition, we have also observed that the presence of a variant GPIIb allele (ILE843SER) indicates, with a similar probability, that a subject may be at risk for acquiring a neurological disease, such as AD. Importantly, these genes may act in synergy and when used together as a prognostic tool, predict, with even greater probability, a subject's risk for a neurological disease, such as AD.

One of the advantages of the invention is that a subject at risk for a neurological disease may be identified and, if appropriate, administered therapeutics without waiting for debilitating symptoms of them required for definitive diagnosis to occur. Initially, treatment of a subject having a variant allele described herein may involve monitoring of the subject for other risk factors and/or symptoms. Alternatively, a

subject at high risk for a neurological disease may be treated prophylactically, with therapies known in the art, in order to delay, inhibit, or prevent the onset of disease. In one approach, the presence of a variant GPIIIa and/or variant GPIIb allele is rapidly determined using a sensitive PCR assay and, alone or in combination with a  
5 determination of other risk factors associated with a neurological disease, this determination is used to determine if a prophylactic treatment therapy should be invoked.

The prediction of drug efficacy may involve cholinomimetic therapies, for example, tacrine, or non-cholinomimetic therapies, for example, a vasopressinergic  
10 drug. The invention provides a treatment protocol that utilizes one of the following therapies for a neurological disease: probucol, a monoamine oxidase inhibitor, muscarinic agonist, neurotrophic factor, noradrenergic factor, antioxidant, anti-inflammatory, corticotrophin-releasing hormone (CRH), somatostatin, substance P, neuropeptide Y, or thyrotrophin-releasing hormone (TRH).

15 The findings described herein indicate the predictive value of a variant GPIIIa and/or variant GPIIb allele in treating patients at risk for a neurological disease, such as Alzheimer's disease (AD). In addition, because the underlying mechanism influenced by the variant GPIIIa and/or variant GPIIb allele status is not disease-specific, the GPIIIa and/or GPIIb allele-status is suitable for making patient  
20 predictions for non-AD neurological diseases as well.

The following examples, which describe preferred techniques and experimental results, are provided for the purpose of illustrating the invention, and should not be construed as limiting.

#### 25 EXAMPLE 1

##### Methods for Determining the Presence of a Variant GPIIIa Allele or Variant GPIIb Allele

We have found that both the variant GPIIIa allele and GPIIb allele have strong predictive value for identifying a subject at risk for a neurological disease (e.g.,

Alzheimer's disease). This predictive value is even stronger when these variant alleles in both genes occur together in a given subject. To demonstrate the effectiveness of the variant GPIIIa and/or variant GPIIb allele for identifying subjects with such a disease risk, we determined the allele frequency of either variant allele in a large number of subjects diagnosed with Alzheimer's disease (N=136) as compared to age-matched healthy controls (N=70).

### *GPIIIa Genotyping*

We genotyped each of the above patients for the presence of a variant GPIIIa allele using the polymerase chain reaction method (PCR). In particular, genotyping was carried out by subjecting nucleic acid samples encoding the GPIIIa gene to a polymerase chain reaction (PCR) amplification step followed by another round of PCR amplification using a nested PCR protocol. The first round of PCR amplification was conducted using outside primers PlA2-4 (5' -AGA CTT CCT CCT CAG ACC TCC ACC T-3' (SEQ ID NO: 9)) and PlA2-5 (5' -TAA ACT CTT AGC TAT TGG GAA GTG GTA-3' (SEQ ID NO: 10)) and using reaction conditions that included a heating step at 90°C for 1 min., followed by another heating step at 95°C for 1 min., followed by 45 cycles of 94°C for 25 sec., 45°C for 55 sec., 72°C for 45 sec., and a final extension step at 72°C for 3 min. Next, a 1 µl aliquot of the first PCR reaction was used for conducting the subsequent nested PCR reaction under the same conditions except that the amplification step performed at 45°C was changed to 48°C and the oligonucleotides PlA2-1 (5' -TTC TGA TTG CTG GAC TTC TCT T-3' (SEQ ID NO: 11)) and PlA2-2 (5' -TCT CTC CCC ATG GCA AAG AGT-3' (SEQ ID NO: 12)) were used.

When amplified GPIIIa DNA isolated from the subjects described above was analyzed, we observed a C nucleotide at base position 192 only in nucleic acids encoded by the variant GPIIIa allele (or PlA2 form) and this created a new Msp I restriction site (see Figs. 1 and 2). Subsequent restriction enzyme analysis of nucleic acids generated by PCR showed that Msp I digestion permitted clear discrimination

between the type (PIA1) and mutant form (PIA2) of GPIIIa and individuals could thus be genotyped.

Specifically, a 5 µl aliquot of the resultant amplified PCR reaction product was digested with 5 units of the restriction enzyme Msp I and the resultant DNA products were analyzed using agarose gel electrophoresis and visualized by ethidium bromide staining. Another Msp I site, common to both wild-type and variant GPIIIa alleles, was used as an internal control to insure the completion of Msp I digestion. Using this protocol, three banding patterns were observed based on whether the subject was homozygous wild-type (T/T), heterozygous mutant (C/T), or homozygous mutant (C/C) for the variant GPIIIa allele (LEU33PRO). The banding pattern for the homozygous wild-type consisted of two DNA fragments of 222 bp and 38 bp in length. The banding pattern for the homozygous mutant genotype consisted of three fragments of 175 bp, 49 bp, and 38 bp in length. Accordingly, the banding pattern for the heterozygous mutant genotype consisted of four fragments of 224 bp, 175 bp, 49 bp, and 38 bp in length. A GPIIIa genotype (LEU33PRO) was determined for each subject in the study and analyzed for its predictive value (Examples 2 and 3).

#### *GPIIb Genotyping*

Each of the above the samples from the patients described above were genotyped for the presence of a variant GPIIb allele using the conditions above with the following modifications. Genotyping was carried out using the same PCR conditions above except that primers A (5'-CTG TCA ACC CTC TCA AGG TAA (SEQ ID NO: 13)) and B (5'-GCC GGG TGA ATG GGG GAG GGG CTG GCG (SEQ ID NO:14)) were used.

Following the PCR amplification reaction, DNA products were digested with the restriction enzyme Hae II (according to the manufacturer) and resultant products were resolved using 3% Nusieve™ gel electrophoresis followed by ethidium bromide staining. As the variant GPIIb nucleic acid encodes an additional Hae II site, distinctive banding patterns were observed based on whether the subject was wild-type

(T/T; 180 bp only), heterozygous mutant (C/T; 180, 155, and 25 bp), or homozygous mutant (C/C; 155 and 25 bp) for the GPIIb allele (ILE843SER).

#### *GPIIIa and GPIIB Phenotyping*

5 For either the GPIIIa (LEU33PRO) or GPIIb (ILE843SER) gene product, detection of the variant polypeptide may be performed (and a genotype thus inferred) using variant polypeptide specific antibodies as described in the art (see, e.g., Weiss et al., *Tissue Antigens* 46:374-381 (1995); Lyman et al., *Blood* 75:2343-2348 (1990)).

In addition to the above-mentioned methods, the methods provided in U.S. Patent No. 5,935,781; any of the pending applications (Serial Nos. 08/766,975; 10 US97/22699; 09/160,462; 08/991,850; 19/334,489; 60/145,602) and following references (Brindle N. et al., *Hum. Mol. Genet.* 7:933-935 (1998); Singleton et al., *Hum Mol Genet* 7:937-939 (1998); Lehmann et al., *Hum. Mol. Genet.* 6:1933-1936 (1997); Richard et al., *Lancet* 349:539 (1997); and Gustincich S, et al., *Biotechniques* 15 11(3):298-300 (1998)) may also be used.

#### Example 2

##### Use of the Variant GPIIIa Allele in Determining a Subjects's Risk for Alzheimer's Disease

20 We have discovered that the presence of a variant GPIIIa allele (LEU33PRO) contributes an individual's risk for the development of Alzheimer's disease. To reach this conclusion, we compiled the GPIIIa genotypes for 135 Alzheimer's disease subjects and 69 age-matched healthy controls (Table 1) and analyzed the distribution 25 of variant GPIIIa alleles in control subjects versus subjects with disease. As shown in Table 1, a significant number of subjects diagnosed with Alzheimer's disease had at least one mutant GPIIIa allele.



Table 1

GPIIIa Nucleotide Dimorphism in Controls vs. Subjects with Alzheimer's Disease (AD)

Genotype	C/C (homozygous mt)	C/T (heterozygous mt)	T/T (wild-type)
Control	1	13	55
AD	2	46	87

In Table 2 we present the total number of subjects having at least one variant GPIIIa allele as a function of the subject's disease status. This data shows that the occurrence of a variant GPIIIa allele in a subject with Alzheimer's disease is more than twice as high as in age-matched healthy controls (the odds ratio (O.R.) is 2.17). The Yates value calculated for this data set indicates that this distribution occurring by chance alone is remote (4%). These data predict a strong correlation between the presence of the variant GPIIIa allele and the occurrence of Alzheimer's disease in a given subject.

Table 2

Chi Square for GPIIIa Allelic Frequency in Controls vs. Subjects with  
Alzheimer's Disease (AD)

	AD	Control
C/C or C/T (Mutant Genotypes)	48	14
T/T (Wild-Type Genotype)	87	55

Yates = 0.037

O.R. = 2.17

In Table 3 the data is shown as the total number of mutant alleles (a C at base position 192) versus wild-type alleles (a T at position 192) occurring in subjects of each health group (i.e., control vs. AD). Stated in another way, each mutant allele is counted and a frequency of occurrence (ranging from 0-1.0) is calculated for the likely appearance of this allele in either a healthy subject or a subject with Alzheimer's disease. A percent occurrence is obtained by multiplying the frequency factor by 100. Thus, the frequency of the variant GPIIIa allele occurring in subjects diagnosed with Alzheimer's disease was 18.5 % ( $0.185 \times 100$ ) as compared to only 11% in healthy age-matched controls.

Table 3

Variant GPIIIa Allele Frequency in Controls vs. Subjects with Alzheimer's Disease (AD)

	C (Mutant Alleles)	T (Wild-Type Alleles)
Control	0.11 (15/138)	0.89 (123/138)
AD	0.185 (50/270)	0.815 (220/270)

Finally, as shown in Tables 4-9, we examined a number of silent mutations (i.e., a wild-type protein is encoded from a mutated nucleic acid) found within the coding region of the GPIIIa gene and found no correlation (the odds ratios are all around 1) between AD and the presence of these mutations. These studies indicate that it is likely that the GPIIIa polypeptide, and not the nucleic acid, plays a possible role in AD. Accordingly, nucleic acid changes that result in amino acid alterations are more likely to be predictive of neurological disease or a predisposition to neurological disease.

Table 4

Val 381 Val Silent Mutation (A-C at base 1159) Genotype of Normal Subjects  
vs. Patients with AD

	AA wild-type	AC heterozygous mt	CC homozygous mt
Alzheimer's cases	51	62	23
Control	26	35	9

Table 5

Odds Ratio and Chi-Square Analysis of the Val 381 Val Silent Mutation  
Occurring in Patients with AD as Compared to Controls

	AD	Control
CX	85	44
AA	51	26

Chi-square = 0.92

O.R. = 0.98

Table 6

Glu 511 Glu Silent Mutation (A-G at base 1549) Genotype of Normal Subjects  
vs. Patients with AD

	AA wild-type	AG heterozygous mutant	GG homozygous mt
Alzheimer's cases	0	36	33
Control	0	66	69

Table 7

Odds Ratio and Chi-Square Analysis of the Glu 511 Glu Silent Mutation  
Occurring in Patients with AD as Compared to Controls

	AD	Control
CX	66	36
AA	69	33

Chi-square = 0.76

O.R. = 0.88

Table 8

Arg 515 Arg Silent Mutation (G-C at base 1161) Genotype of Normal Subjects  
vs. Patients with AD

	AA wild-type	AG heterozygous mt	GG homozygous mt
Alzheimer's cases	5	28	34
Control	19	50	64

Table 9

Odds Ratio and Chi-Square Analysis of the Arg 515 Arg Silent Mutation  
Occurring in Patients with AD as Compared to Controls

	AD	Control
CX	69	33
AA	64	34

Chi-square = 0.84

O.R. = 1.11

### EXAMPLE 3

Use of the Variant GPIIb Allele Alone and in Combination with the Variant GPIIIa  
Allele in Determining a Subject's Risk for Alzheimer's Disease

Using the techniques presented in Example 1, we determined the GPIIb  
genotype of patients with AD and normal control subjects (Table 10).

Table 10

Variant GPIIb Genotype in Normal Subjects vs. Patients with AD

Genotype	GG (homozygous mt.)	GT (heterozygous mt.)	TT (wild-type)
Alzheimer's Cases	15	71	50
Control	8	28	34

We observed that a significant number of subjects with AD had at least one mutant GPIIb allele. A chi-square and odds ratio analysis was performed on this data set (Table 11). A significant increase in the odds ratio (p value of 0.10) was seen in patients with AD as compared to age-matched healthy control subjects. This supports the notion that the GPIIb gene may be involved in the development of neurological disease such as AD.

Table 11

Odds Ratio and Chi-Square Analysis of the GPIIb Allele Occurring in Normal Subjects vs. Patients with AD

CX versus TT		
Genotypes	Alzheimer's Cases	Control
GX (mutant genotypes)	86	36
TT(wild-type)	50	34

O.R. = 1.62 (C.I. 0.91 to 2.91)

Chi-square p=0.10

Given these findings we decided to explore the possibility that the predictive value of the variant GPIIIa allele and the variant GPIIb allele could be used together in

predicting a neurological disease risk. The occurrence of these alleles appearing individually or together in normal subjects versus patients with AD is presented below (Table 12).

Table 12

GPIIIa (Leu33Pro) / GPIIb (Ile843Ser) Genotypes in Normal Subjects vs. Patients with AD

GPIIIa (L33P)	GPIIb (I843S)	Control	AD	O.R.	P value
-	-	27	34	Ref.	---
-	+	29	53	1.45	0.28
+	-	7	16	1.82	0.25
+	+	7	33	3.74	0.005

Importantly, we found that in addition to the GPIIIa or GPIIb variant alleles being present at high levels in patients with AD (with an odds ratio of 1.82 and 1.45, respectively), together these alleles were present at an even higher level (with an odds ratio of 3.74). Stated another way, patients with AD are almost 4-fold more likely to have mutations in both the GPIIIa and GPIIb allele than normal control subjects. Thus, we have determined that there is an added predictive value or synergy in using both of these alleles when evaluating a subject for a neurological disease risk.

#### EXAMPLE 4

##### Use of the Variant GPIIIa and GPIIb Alleles for Prognosis in Alzheimer's Disease

We believe that the method of the invention can be used as a powerful prognostic tool for the treatment of Alzheimer's disease. For example, subjects can be tested at an early asymptomatic age for the presence of a variant GPIIIa and/or GPIIb allele and administered an appropriate prophylactic therapy. Initially, for asymptomatic subjects, this may involve a characterization of other risk factors



associated with Alzheimer's disease, avoidance of environmental risk factors, and/or close monitoring. Accordingly, a subject may be characterized as a candidate for prophylactic therapies that can delay, inhibit, or prevent degenerative neurological symptoms. Further, either alone or in combination with other health data, the variant GPIIIa and GPIIb alleles can be used to predict a subject's outcome by comparing the subjects GPIIIa and GPIIb genotypes (and other health data) to a patient database containing the GPIIIa and GPIIb genotypes (and other health data) of similarly afflicted subjects. Based on this database comparison, a subject's likely outcome, i.e., progression of disease, cure rate, response to therapy, morbidity and mortality, can be statistically assessed.

Thus, our results demonstrate that the presence of the variant GPIIIa and/or GPIIb alleles can afford subjects at risk for a neurological disease (e.g., Alzheimer's disease) the ability to start prophylactic therapies before disease strikes. Ideally, the risk of Alzheimer's disease is calculated for all individuals when they are asymptomatic, young adults and well before the onset of measurable symptoms. Then preventive therapies are invoked, as the individual ages, in order to stop or lessen the progression of Alzheimer's disease later in life.

#### Other Embodiments

The invention described herein provides a method for treating subjects with a neurological disease risk by determining a subject's GPIIIa and/or GPIIb genotype and providing an appropriate therapy based on that determination. We believe that the predictive value of these alleles may also include other variant GPIIIa or GPIIb alleles associated with a neurological disease (e.g., Alzheimer's disease) and this may be readily determined using the methods of the invention. For example, any other variant GPIIIa allele may be detected using the methods described in Example 1. Known polymorphisms in GPIIIa that may be determined to be variants using the methods of the invention are: GPIIIa (ARG62Term), GPIIIa (LEU117TRP), GPIIIa (ASP119TYR), GPIIIa (SER162LEU), GPIIIa (ARG214GLN), GPIIIa (ARG214TRP), GPIIIa (CYS374TYR), GPIIIa (PRO407ALA), GPIIIa

(ARG636CYS), and GPIIIA (SER752PRO). Using the guidance provided in Example 2, one can calculate the allelic frequency of the variant GPIIIa allele/s in patients diagnosed with Alzheimer's disease, as compared to healthy control subjects, and determine if the particular variant GPIIIa allele is over represented in patients with disease. Likewise, known polymorphisms in GPIIb may also be exploited, alone, or in combination with the above GPIIIa mutations. GPIIb variants which may be tested are: GPIIb (LEU183PRO), GPIIb (GLY242ASP), GPIIb (PHE289SER), GPIIb (GLU324LYS), GPIIb (ARG327HIS), GPIIb (GLY418ASP), GPIIb (ARG553TERM), GPIIb (ILE565THR), GPIIb (GLN747PRO), and GPIIb (SER870TERM). Furthermore, the predictive value of these alleles can then be assessed and, if appropriate, used alone or in combination with other risk factors for the treatment of Alzheimer's disease.

In addition, while the methods described herein are preferably used for the treatment of human subjects. Non-human animals (e.g., pets and livestock) may also be treated using the methods of the invention.

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

Other embodiments are within the claims.

What is claimed is:

CLAIMS

1. A method for identifying a subject at risk for a neurological disease comprising the following:

a) identifying said subject,

b) determining the genotype or phenotype of the GPIIIa or GPIIb locus of said subject, and

c) determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform,

wherein the presence of said variant GPIIIa allele or isoform or said variant GPIIb allele or isoform is indicative of said subject having an increased risk of said neurological disease.

2. A method for diagnosing a subject with a neurological disease comprising the following:

a) identifying said subject,

b) determining the genotype or phenotype of the GPIIIa or GPIIb locus of said subject, and

c) determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform,

wherein the presence of said variant GPIIIa allele or isoform or said variant GPIIb allele or isoform is indicative of said subject having a likelihood of said neurological disease.

3. A method for characterizing the genotype of at least one subject involved in a clinical trial of a therapy for the treatment of a neurological disease comprising the following:

a) identifying said subject,

a) determining the genotype or phenotype of the GPIIIa or GPIIb locus of said subject before, during, or after said clinical trial, and

b) determining the presence of a variant GPIIIa or a variant GPIIb allele or

isoform,

wherein the presence of said variant GPIIIa allele or isoform or said variant GPIIb allele or isoform places said subject into a subgroup for said clinical trial.

5 4. A method for treating a subject with a neurological disease comprising the following:

a) identifying said subject,

b) determining the genotype or phenotype of the GPIIIa or GPIIb locus of said subject,

10 c) determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform, and

d) determining the preferred therapy for the treatment of said neurological disease.

15 5. A method for treating a subject at risk for a neurological disease comprising the following:

a) identifying said subject,

b) determining the genotype or phenotype of the GPIIIa or GPIIb locus of said subject,

20 c) determining the presence of a variant GPIIIa or a variant GPIIb allele or isoform, and

d) determining the GPIIIa or GPIIb allele status of said subject,  
wherein said allele status is predictive of patient outcome or drug efficacy.

25 6. The method of claim 1, 2, 3, 4, or 5, wherein said method comprises determining the presence of both said variant GPIIIa allele or isoform and said variant GPIIb allele or isoform.

30 7. The method of claim 1, 2, 3, 4, or 5, wherein said neurological disease is Alzheimer's disease (AD).

8. The method of claim 1, 2, 3, 4, or 5, wherein said neurological disease is a non-AD neurological disease.

5 9. The method of claim 1, 2, 3, 4, or 5, wherein said neurological disease is selected from the group consisting of Alzheimer's disease, neurofibromatosis, Huntington's disease, depression, amyotrophic lateral sclerosis, multiple sclerosis, stroke, Parkinson's disease, and multi-infarct dementia.

10 10. The method of claim 1, 2, 3, 4, or 5, wherein said determining is performed using a nucleic acid that specifically binds a nucleic acid encoded by said variant GPIIIa allele.

15 11. The method of claim 1, 2, 3, 4, or 5, wherein said determining is performed using a nucleic acid that specifically binds a nucleic acid encoded by said variant GPIIb allele.

20 12. The method of claim 1, 2, 3, 4, or 5, wherein said determining is performed using an antibody that specifically binds a polypeptide encoded by said variant GPIIIa allele, but does not bind a polypeptide encoded by a wild-type GPIIIa allele.

25 13. The method of claim 1, 2, 3, 4, or 5, wherein said determining is performed using an antibody that specifically binds a polypeptide encoded by said variant GPIIb allele, but does not bind a polypeptide encoded by a wild-type GPIIb allele.

14. The method of claim 1, 2, 3, 4, or 5, wherein said variant GPIIIa allele has a point mutation at nucleotide base 192 of SEQ ID NO: 2.

30 15. The method of claim 1, 2, 3, 4, or 5, wherein said variant GPIIb allele has a

point mutation at nucleotide base 2622 of SEQ ID NO: 6.

- 5
16. The method of claim 1, 2, 3, 4, or 5, wherein said variant GPIIIa allele encodes a polypeptide with a proline at amino acid position 33 of SEQ ID NO: 4.
17. The method of claim 1, 2, 3, 4, or 5, wherein said variant GPIIb allele encodes a polypeptide with a serine at amino acid position 843 of SEQ ID NO: 8.
- 10 18. The method of claim 3, wherein said genotype or phenotype is indexed against the efficacy or side effects of said therapy.

1/8

```

1  gcgggaggcg gacgagatgc gagcgcgggc gcgggccccg ccgctctggg cgactgtgct
61 ggcgctgggg gcgctggcgg gcgttggegt aggaggggcc aacatctgta ccacgcgagg
121 tgtgagctcc tgccagcagt gcctggctgt gagccccatg tgtgcctggt gctctgatga
181 ggccctgcct ctgggctcac ctgctgtga cctgaaggag aatctgtga aggataactg
241 tgccccagaa tccatcgagt tccagtgag tgaggccccg gtactagagg acaggccccct
301 cagcgacaag ggctctggag acagctccca ggtcactcaa gtcagtcccc agaggattgc
361 actccggctc cggccagatg attcgaagaa tttctccatc caagtgcggc aggtggagga
421 ttaccctgtg gacatctact acttgatgga cctgtcttac tccatgaagg atgatctgtg
481 gagcatccag aacctgggta ccaagctggc caccagatg cgaaagctca ccagtaacct
541 gccgattggc ttcggggcat ttgtggagaa gcctgtgtca ccatacatgt atatctcccc
601 accagaggcc ctcgaaaacc cctgctatga tatgaagacc acctgcttgc ccatgtttgg
661 ctacaaacac gtgtgacgc taactgacca ggtgacccgc ttcaatgagg aagtgaagaa
721 gcagagtgtg tcacggaacc gagatgcccc agagggtggc tttgatgcca tcatgcaggc
781 tacagtctgt gatgaaaaga ttggctggag gaatgatgca tcccacttgc tgggtgttac
841 cactgatgcc aagactcata tagcattgga cggaggctg gcaggcattg tccagcctaa
901 tgacggcgag tgtcatgttg gtagtgacaa tcattactct gcctccacta ccattgatta
961 tccctctttg gggtgatga ctgagaagac atcccagaaa aacatcaatt tgatctttgc
1021 agtgactgaa aatgtagtca atctctatca gaactatagt gagctcatcc cagggaccac
1081 agttgggggt ctgtccatgg attccagcaa tgtcctccag ctcatgtttg atgcttatgg
1141 gaaaatccgt tctaaagtag agctggaagt gcgtgacctc cctgaagagt tgtctctatc
1201 cttcaatgcc acctgcctca acaatgaggt catccctggc ctcaagtctt gtatgggact
1261 caagattgga gacacggtga gcttcagcat tgaggccaag gtgagaggct gtccccagga
1321 gaaggagaag tcctttacca taaagccgt gggcttcaag gacagcctga tcgtccaggt
1381 cacctttgat tgtgactgtg cctgccaggc ccaagctgaa cctaatagcc atcgctgcaa
1441 caatggcaat gggacctttg agtgtggggg atgccgttgt gggcctggct ggctggatc
1501 ccagtgtgag tgctcagagg aggactatcg cccttcccag caggacgaat gcagcccccg
1561 ggagggtcag cccgtctgca gccagcgggg cgagtgcctc tgtggtcaat gtgtctgcca
1621 cagcagtgac tttggcaaga tcacgggcaa gtactgagag tgtgacgact tctcctgtgt
1681 ccgctacaag ggggagatgt gctcaggcca tggccagtgc agctgtgggg actgctctgtg
1741 tgactccgag tggaccggct actactgcaa ctgtaccacg cgtactgaca cctgcatgtc
1801 cagcaatggg gcgtgtgca gcggcgcgg caagtgtgaa tgtggcagct gtgtctgtat
1861 ccagccgggc tcctatgggg acacctgtga gaagtgcgcc acctgcccag atgcctggac
1921 ctttaagaaa gaatgtgtgg agtgaagaa gtttgaccgg gagccctaca tgaccgaaaa
1981 tacctgcaac cgttactgcc gtgacgagat tgagtcagtg aaagagctta aggacactgg
2041 caagatgca gtgaattgta cctataagaa tgaggatgac tgtgtcgtca gattccagta
2101 ctatgaagat tctagtggaa agtccatcct gtatgtggta gaagagccag agtgtcccaa
2161 gggccctgac atcctgggtg tctgtctctc agtgaagggg gccattctgc tcattggcct
2221 tgccgccctg ctcatctgga aactcctcat caccatccac gaccgaaaag aattcgctaa
2281 atttgaggaa gaacgcgcca gagcaaaatg ggacacagcc aacaaccac tgtataaaga
2341 ggccacgtct accttcacca atatcacgta ccggggcact taatgataag cagtcacctt
2401 cagatcatta tcagcctgtg ccacgattgc aggagtccct gccatcatgt ttacagagga
2461 cagtatttgt ggggagggat ttgggctca gagtggggta ggttgggaga atgtcagtat
2521 gtggaagtgt gggctctgtg gtgtgtatgt gggggtctgt gtgtttatgt gtgtgtgtg
2581 tgtgtgggag tgtgtaattt aaaattgtga tgtgtcctga taagctgagc tccttagcct
2641 ttgtcccaga atgcctcctg caggattctt tectgcttag cttgagggtg actatggagc
2701 tgagcagggtg ttcttcatta cctcagtgag aagccagctt tcctcatcag gccattgtcc
2761 ctgaagagaa gggcagggtc gaggcctctc attccagagg aaggacacc aagccttggc
2821 tctaccctga gttcataaat ttatggttct caggcctgac tctcagcagc tatggtagga
2881 actgctgggc ttggcagccc ggtcatctg tacctctgcc tcctttcccc tccctcaggc
2941 cgaaggagga gtcaggggaga gctgaactat tagagctgcc tgtgcctttt gccatccctt
3001 caaccagct atggttctct cgcaaggga gtccttgcaa gctaattctt tgacctgttg
3061 ggagtggaga tgtctgggcc actcaggggt cattcatggc ctgggggatg taccagcatc
3121 tcccagttca taatcacaa ccttcagatt tgccttattg gcagctctac tctggaggtt
3181 tgtttagaag aagtgtgtca cccttaggcc agcaccatct ctttacctcc taattccaca

```

Fig. 1

SUBSTITUTE SHEET (RULE 26)

```
3241 ccctcactgc tgtagacatt tgctatgagc tggggatgtc tctcatgacc aaatgctttt
3301 cctcaaaggg agagagtgtt attgtagagc cagaggtctg gccctatgct tccggcctcc
3361 tgtccctcat ccatagcacc tccacatacc tggccctgag ccttgggtgtg ctgtatccat
3421 ccatggggct gattgtattt accttctacc tcttggctgc cttgtgaagg aattattccc
3481 atgagttggc tgggaataag tgccaggatg gaatgatggg tcagttgtat cagcacgtgt
3541 ggcctgttct tctatgggtt ggacaacctc attttaactc agtctttaat ctgagaggcc
3601 acagtgcaat tttattttat ttttctcatg atgaggtttt cttacttaa aagaacatgt
3661 atataaacat gcttgcatta tatttgtaaa tttatgtgta tggcaaagaa ggagagcata
3721 ggaaaccaca cagacttggg cagggtagag acactcccac ttggcatcat tcacagcaag
3781 tcactggcca gtggctggat ctgtgagggg ctctctcatg atagaaggct atggggatag
3841 atgtgtggac acattggacc tttcttgagg aagagggact gttcttttgt cccagaaaag
3901 cagtggctcc attggtgttg acatacatcc aacattaaaa gccaccccca aatgcccaag
3961 aaaaaaagaa agacttatca acatttgttc catgagg
```

Fig. 1 cont.



3/8

```

1  gcgaggagcg gacgagatgc gagcgcgccc gcgggccccg ccgctctggg cgactgtgct
61  ggcgctgggg ggcgtggcgg gcggtggcgt agggggggcc aacatctgta ccacgcgagg
121  tgtgagctcc tgccagcagt gcctggctgt gagccccatg tgtgectggt gctctgatga
181  ggccctgcct ccg ggctcac tcgctgtga cctgaaggag aatctgctga aggataactg
241  tgccccagaa tccatcgagt tcccagtgag tgaggccccg gtactagagg acaggccctt
301  cagcgacaag ggctctggag acagctccca ggtcactcaa gtcagtcccc agaggattgc
361  actccggctc cggccagatg attcgaagaa tttctccatc caagtgcggc aggtggagga
421  ttaccctgtg gacatctact acttgatgga cctgtcttac tccatgaagg atgatctgtg
481  gagcatccag aacctgggta ccaagctggc caccagatg cgaaagctca ccagtaacct
541  gcggtattggc ttcggggcat ttgtggacaa gcctgtgtca ccatacatgt atatctcccc
601  accagaggcc ctcgaaaacc cctgctatga tatgaagacc acctgttgc ccattgtttg
661  ctacaaacac gtgtcgacgc taactgacca ggtgaccgc ttcaatgagg aagtgaagaa
721  gcagagtgtg tcacggaacc gagatgcccc agagggtggc ttgatgcca tcatgcaggc
781  tacagtctgt gatgaaaaga ttggctggag gaatgatgca tcccacttgc tgggttttac
841  cactgatgcc aagactcata tagcattgga cggaaggctg gcaggcattg tccagcctaa
901  tgacgggcag tgtcatgttg gtagtgacaa tcattactct gcctccacta ccattggatta
961  tccctctttg gggctgatga ctgagaagct atcccagaaa aacatcaatt tgatctttgc
102  agtgactgaa aatgtagtca atctctatca gaactatagt gagctcatcc caggggaccac
1081  agttggggtt tgcctcatgg attccagcaa tgcctccag ctcatgtttg atgcttatgg
1141  gaaaatccgt tctaaagtag agctggaagt gcgtgacctc cctgaagagt tgtctctatc
1201  cttcaatgcc acctgcctca acaatgaggt catccctggc ctcaagtctt gtatgggact
1261  caagattgga gacacgggtg gcttcagcat tgaggccaag gtgcgaggct gtccccagga
1321  gaaggagaag tcctttacca taaagccctg gggcttcaag gacagcctga tcgtccaggt
1381  cacctttgat tgtgactgtg cctgccaggc ccaagctgaa cctaatagcc atcgctgcaa
1441  caatggcaat gggacctttg agtgtggggt atgccgttgt gggcctggct ggctgggatc
1501  ccagtgtgag tgcctcagag aggactatcg ccttcccag caggacgaat gcagccccg
1561  ggagggtcag cccgtctgca gccagcgggg cgagtgcctc tgtggtcaat gtgtctgacc
1621  cagcagtgac tttggcaaga tcacgggcaa gtactgcgag tgtgacgact tctcctgtgt
1681  ccgctacaag ggggagatgt gctcaggcca tggccagtgc agctgtgggg actgcctgtg
1741  tgactccgac tggaccggtt actactgcaa ctgtaccacg cgtactgaca cctgcatgtc
1801  cagcaatggg ctgctgtgca gcggccgcgg caagtgtgaa tgtggcagct gtgtctgtat
1861  ccagccgggc tccatggggg acacctgtga gaagtcccc acctgcccag atgcctgcac
1921  ctttaagaaa gaatgtgtgg agtgtaagaa gtttgaccgg gagccctaca tgaccgaaaa
1981  tacctgcaac cgttactgcc gtgacgagat tgagtcagtg aaagagctta aggacactgg
2041  caaggatgca gtgaattgta cctataagaa tgaggatgac tgtgtcgtca gattccagta
2101  ctatgaagat tctagtggaa agtccatcct gtatgtggta gaagagccag agtgtcccaa
2161  gggccctgac atcctgggtg tcctgtcttc agtgatgggg gccattctgc tcattggcct
2221  tgccgcccctg ctcatctgga aactcctcat caccatccac gaccgaaaag aattcgctaa
2281  atttgaggaa gaacgcgcca gagcaaaatg ggacacagcc aacaaccac tgtataaaga
2341  ggccacgtct accttcacca atatcacgta ccggggcact taatgataag cagtcacctt
2401  cagatcatta tcagcctgtg ccacgattgc aggagtccct gccatcatgt ttacagagga
2461  cagtatttgt ggggagggat ttggggctca gagtggggta ggttgggaga atgtcagtat
2521  gtggaagtgt gggctctgtg gtgtgtatgt gggggtctgt gtgtttatgt gtgtgtgtg
2581  tgtgtgggag tgtgtaattt aaaattgtga tgtgtcctga taagctgagc tccttagcct
2641  ttgtcccaga atgcctcctg cagggattct tcctgcttag cttgagggtg actatggagc
2701  tgagcagggt ttcttcatta cctcagttag aagccagctt tcctcatcag gccattgtcc
2761  ctgaagagaa gggcagggct gaggcctctc attccagagg aaggacacc aagccttggc
2821  tctaccctga gttcataaat ttatggttct caggcctgac tctcagcagc tatggtagga
2881  actgctgggc ttggcagccc gggctcatctg tacctctgce tcctttcccc tccctcagge
2941  cgaaggagga gtcagggaga gctgaactat tagagctgcc tgtgcctttt gccatccctt
3001  caaccagct atggttctct cgcaaggga gtccttgcaa gctaattctt tgacctgttg
3061  ggagttagga tgtctgggcc actcaggggt cattcatggc ctgggggatg taccagcatc
3121  tcccagttca taatcacaac ccttcagatt tgcttattg gcagctctac tctggagggt
3181  tgtttagaag aagtgtgtca cccttaggcc agcaccatct ctttacctec taattccaca

```

Fig. 2

SUBSTITUTE SHEET (RULE 26)

4/8

```
3241 ccetcaactgc tgtagacatt tgctatgagc tggggatgtc tctcatgacc aaatgctttt
3301 cctcaaaggg agagagtgtc attgttagagc cagaggctctg gccctatgct tccggcctcc
3361 tgtccctcat ccatagcacc tccacatacc tggccctgag ccttggtgtg ctgtatccat
3421 ccatggggct gattgtatct accttctacc tcttggtctgc cttgtgaagg aattattccc
3481 atgagttggc tgggaataag tgccaggatg gaatgatggg tcagttgtat cagcacgtgt
3541 ggcctgttct tctatgggtt ggacaacctc attttaactc agtctttaat ctgagaggcc
3601 acagtgaat tttattttat ttttctcatg atgaggtttt cttaacttaa aagaacatgt
3661 atataaacat gcttgcatga tatttgtaaa tttatgtgta tggcaaagaa ggagagcata
3721 ggaaaccaca cagacttggg cagggtagag aactcccac ttggcatcat tcacagcaag
3781 tcaactggcca gtggctggat ctgtgagggg ctctctcatg atagaaggct atggggatag
3841 atgtgtggac acattggacc tttcctgagg aagaggggact gttcttttgt cccagaaaag
3901 cagtggctcc attggtgttg acatacatcc aacattaaaa gccaccccca aatgcccaag
3961 aaaaaaagaa agacttatca acatttggtc catgagg
```

Fig. 2 cont.

5/8

```

1 MRARPRPRPL WTVLALGAL AGVGVGGPNI CTTRGVSSCQ QCLAVSPMCA WCSDEALPLG 60
61 SPRCDLKENL LKDNCAPESE EFPVSEARVL EDRPLSDKGS GDSSQVTQVS PQRIALRLRP 120
121 DDSKNFSIQV RQVEDYPVDI YYLMDLSYSM KDDLWSIQNL GTKLATQMRK LTSNLRIGFG 180
181 AFVDKPVSPY MYISPPEALE NPCYDMKTTC LPMFGYKHVL TLTDQVTRFN EEVKKQSVSR 240
241 NRDAPEGGFD AIMQATVCDE KIGWRNDASH LLVFTTDAKT HIALDGRLAG IVQPNQGQCH 300
301 VGSDNHYSAS TTMDYPSLGL MTEKLSQKNI NLIFAVTENV VNLYQNYSEL IPGTTVGVL 360
361 MDSSNVQLI VDAYGKIRSK VELEVRDLPE ELSLSFNATC LNNEVIPGLK SCMGLKIGDT 420
421 VSFSIEAKVR GCPQEKEKSF TIKPVGFKDS LIVQVTFDCD CACQAQAEPN SHRCNNNGGT 480
481 FECGVCRCGP GWLGSQCECS EEDYRPSQQD ECSPREGQPV CSQRGECLCG QCVCHSSDFG 540
541 KITGKYCEDF DFSCVRYKGE MCSGHGQCSC GDCLCDSWT GYYCNCTTTRT DTCMSSNGLL 600
601 CSGRGKCECG SCVCIQPGSY GDTCEKCPTC PDACTFKKEC VECKKFDREP YMTENTCNRY 660
661 CRDEIESVKE LKDTGKDAVN CTYKNEDDCV VRFQYYEDSS GKSILYVVEE PECPKGPDIL 720
721 VVLLSVMGAI LLIGLAALLI WKLLITIHDR KEFAKFEEER ARAKWDTANN PLYKEATSTF 780
781 TNITYRGT

```

Fig. 3

```

1 MRARPRPRPL WTVLALGAL AGVGVGGPNI CTTRGVSSCQ QCLAVSPMCA WCSDEALPPG 60
61 SPRCDLKENL LKDNCAPESE EFPVSEARVL EDRPLSDKGS GDSSQVTQVS PQRIALRLRP 120
121 DDSKNFSIQV RQVEDYPVDI YYLMDLSYSM KDDLWSIQNL GTKLATQMRK LTSNLRIGFG 180
181 AFVDKPVSPY MYISPPEALE NPCYDMKTTC LPMFGYKHVL TLTDQVTRFN EEVKKQSVSR 240
241 NRDAPEGGFD AIMQATVCDE KIGWRNDASH LLVFTTDAKT HIALDGRLAG IVQPNQGQCH 300
301 VGSDNHYSAS TTMDYPSLGL MTEKLSQKNI NLIFAVTENV VNLYQNYSEL IPGTTVGVL 360
361 MDSSNVQLI VDAYGKIRSK VELEVRDLPE ELSLSFNATC LNNEVIPGLK SCMGLKIGDT 420
421 VSFSIEAKVR GCPQEKEKSF TIKPVGFKDS LIVQVTFDCD CACQAQAEPN SHRCNNNGGT 480
481 FECGVCRCGP GWLGSQCECS EEDYRPSQQD ECSPREGQPV CSQRGECLCG QCVCHSSDFG 540
541 KITGKYCEDF DFSCVRYKGE MCSGHGQCSC GDCLCDSWT GYYCNCTTTRT DTCMSSNGLL 600
601 CSGRGKCECG SCVCIQPGSY GDTCEKCPTC PDACTFKKEC VECKKFDREP YMTENTCNRY 660
661 CRDEIESVKE LKDTGKDAVN CTYKNEDDCV VRFQYYEDSS GKSILYVVEE PECPKGPDIL 720
721 VVLLSVMGAI LLIGLAALLI WKLLITIHDR KEFAKFEEER ARAKWDTANN PLYKEATSTF 780
781 TNITYRGT

```

Fig. 4

SUBSTITUTE SHEET (RULE 26)

6/8

```

1 gatggccaga gctttgtgtc cactgcaagc cctctggcct ctggagtggg tgctgtgtgt
61 cttgggacct tgtgtgtccc ctccagcctg ggccttgaac ctggacccag tgcagctcac
121 cttctatgca ggccccaatg gcagccagtt tggattttca ctggacttcc acaaggacag
181 ccatgggaga gtggccatcg tgggtggcgc ccgcgggacc ctgggccccca gccaggagga
241 gacgggcggc gtgttcctgt gcccctggag ggccgagggc ggccagtgcc cctcgtgtgt
301 ctttgacctc cgtgatgaga ccgaaatgt aggtcccaa actttacaaa ccttcaaggc
361 ccgccaagga ctggggcgct cggtcgtcag ctggagcgac gtcattgtgg cctgcgcccc
421 ctggcagcac tggaaacgtcc tagaaaagac tgaggaggct gagaagacgc ccgtaggtag
481 ctgctttttg gctcagccag agagcggccg ccgcgccgag tactccccct gtcgcgggaa
541 caccctgagc cgcatttacg tggaaaatga ttttagctgg gacaagcggt actgtgaagc
601 gggcttcagc tccgtggtca ctcaggccgc agagctggtg cttggggctc ctggcgctga
661 ttattttctta ggtctcctgg cccaggctcc agttgcggat attttctcga gttaccgccc
721 aggcattcctt ttgtggcacg tgtcctccca gagcctctcc tttgactcca gcaaccaga
781 gtacttcgac ggctactggg ggtactcggg gccgtgggc gagttcgacg gggatctcaa
841 cactacagaa tatgtcgtcg gtgccccac ttggagctgg accctgggag cggtggaat
901 tttggattcc tactaccaga ggctgcacg gctgcgcgca gaggagatgg cgtcgtattt
961 tgggcattca gtgctgtca ctgacgtcaa cggggatggg aggcattgac tgctggtggg
1021 cgctccactg tataatggaga gccgggcaga cccgaaaactg gccgaagtgg ggcgtgtgta
1081 tttgttctctg cagccgcgag gccccacgc gctgggtgcc cccagcctcc tgctcactgg
1141 cacacagctc tatggcgat tcggtctgct catcgacccc ctgggcgacc tcgaccggga
1201 tggctacaat gacattgcag tggctgcccc ctacgggggt cccagtggcc ggggccaagt
1261 gctggtgttc ctgggtcaga gtgaggggct gaggtcacgt ccctcccagg tcctggacag
1321 cccctcccc acaggctctg cctttggctt cctccttcca ggtgcccgtg acatcgatga
1381 caacggatcc ccagacctga tcgtgggagc ttacggggcc aaccaggtgg ctgtgtacag
1441 agctcagcca gtggtgaagg cctctgtcca gctactggtg caagattcac tgaatcctgc
1501 tgtgaagagc tgtgtcctac ctcagaccaa gacaccgtg agctgcttca acatccagat
1561 gtgtgttggg gccactgggc acaacattcc tcagaagcta tccctaaatg ccgagctgca
1621 gctggaccgg cagaagcccc gccagggccg gcggtgtctg ctgctgggct ctcaacaggc
1681 aggcaccacc ctgaacctgg atctgggagg aaagcacagc cccatctgcc acaccaccat
1741 ggcttctctc cgagatgagg cagacttccg ggacaagctg agccccattg tgctcagcct
1801 caatgtgtcc ctacggccca cggaggctgg aatggccccct gctgtcgtgc tgcattggtg
1861 caccatgtg caggagcaga cactgaatcg cctggactct ggggaagatg acgtatgtgt
1921 gccccagctt cagctcactg ccagcgtgac gggctccccg ctcctagtgt gggcagataa
1981 tgtcctggag ctgcagatgg acgcagccaa cgagggcgag ggggcctatg aagcagagct
2041 ggccgtgcac ctgccccagg gcgcccacta catgcgggccc ctaagcaatg tcgagggctt
2101 tgagagactc atctgtaatc agaagaagga gaatgagacc aggggtggtg tgtgtgagct
2161 gggcaacccc atgaagaaga acgcccagat aggaatcgcg atgttggtga gcgtggggaa
2221 tctggaagag ctggggaggt ctgtgtcctt ccagctgcag atacggagca agaacagcca
2281 gaatccaaac agcaagattg tgcgtctgga cgtgccggtc cgggcagagg cccaagtgga
2341 gctgcgaggg aactcctttc cagcctccct ggtggtggca gcagaagaag gtgagagggg
2401 gcagaacagc ttggacagct ggggacccaa agtgagcac acctatgagc tccacaacaa
2461 tggccctggg actgtgaatg gtcttcacct cagcatccac cttccgggac agtcccagcc
2521 ctccgacctg ctctacatcc tggatataca gccccagggg ggcttcagt gcttcccaca
2581 gcctcctgtc aacctctca aggtggactg ggggtgccc atc cccagcc cctcccccat
2641 tcacccggcc catcacaaag gggatcgag acagatcttc ctgccagagc ccgagcagcc
2701 ctcgaggctt caggatccag ttctcgtaag ctgcgactcg gcgcccgtga ctgtggtgca
2761 gtgtgacctg caggagatgg cgcgcgggca gcgggccatg gtcacgggtg tggccttctt
2821 gtggctgccc agcctctacc agaggcctct ggatcagttt gtgctgcagt cgcacgcagt
2881 gttcaacgtg tctccctcc cctatgcggt gccccgctc agcctgcccc gaggggaagc
2941 tcaggtgtgg acacagctgc tccgggcctt ggaggagagg gccattccaa tctggtgggt
3001 gctggtgggt gtgctgggtg gcctgctgct gctcaccatc ctggtcctgg ccatgtggaa
3061 ggtcggtctc ttcaagcgga accggccacc cctggaagaa gatgatgaag agggggagtg
3121 atggtgcagc ctacactatt ctacaggag ggttgggcgt gctacctgca ccgccccttc
3181 tccaacaagt tgctccaag ctttgggttg gagctgttcc attgggtcct cttggtgtcg
3241 tttccctccc aacagagctg ggctaccccc cctcctgctg cctaataaag agactgagcc
3301 ctg

```

Fig. 5

SUBSTITUTE SHEET (RULE 26)

7/8

```

1 gatggccaga gctttgtgtc cactgcaagc cctctggctt ctggagtggg tgctgctgct
61 cttgggacct tgtgctgccc ctcagcctg ggccttgaac ctggaccagc tgcagctcac
121 cttctatgca ggccccaatg gcagccaagt tggattttca ctggacttcc acaaggacag
181 ccatgggaga gtggccatcg tggtagggcg cccgcggacc ctggggccca gccaggagga
241 gacgggcggc gtgttctgt gcccctggag ggccgagggc ggccagtgcc cctcgctgct
301 ctttgacctc cgtgatgaga cccgaaatgt aggcctccaa actttacaaa ccttcaaggc
361 ccgccaagga ctggggggcgt cggtcgtcag ctggagcgac gtcattgtgg cctgcgcccc
421 ctggcagcac tggaacgtcc tagaaaagac tgaggaggct gagaagacgc cctaggttag
481 ctgctttttg gctcagccag agagcgggcg ccgcgcggag tactccccct gtcgcgggaa
541 caccctgagc cgcatttacg tggaaaatga ttttagctgg gacaagcgtt actgtgaagc
601 gggcttcagc tccgtgggtc ctacggcgcg agagctgggt cttggggctc ctggcggcta
661 ttattttcta ggtctcctgg cccaggtccc agttgcggat attttctoga gttaccgccc
721 aggcatacct ttgtggcacg tgctctccca gagectctcc tttgactcca gcaaccagga
781 gtacttcgac ggctactggg ggtactcggg ggccgtgggc gagttcgacg gggatctcaa
841 cactacagaa tatgtcgtcg gtgccccac ttggagctgg accctgggag cgggtgaaat
901 tttggattcc tactaccaga ggctgcacgt gctgcgcgca gagcagatgg cgtcgtatct
961 tgggcattca gtggctgtca ctgacgtcaa cggggatggg aggcatacgc tgctggtggg
1021 cgctccactg tatatggaga gccgggcaag ccgaaaactg gccgaagtgg ggcgtgtgta
1081 tttgttctct cagccgcgag gccccacgc gctgggtgcc cccagcctcc tgcactggg
1141 cacacagctc tatggcgat tgggtctctg catcgacccc ctgggcgacc tcgaccggga
1201 tggctacaat gacattgcag tggctgcccc ctacgggggt cccagtggcc ggggccaagt
1261 gctggtgttc ctgggtcaga gtgagggggt gaggtcacgt cctcccagg tcctggacag
1321 ccccttcccc acaggctctg cctttggctt ctcccttcca ggtgcccgtg acatcgatga
1381 caacggatac ccagacctga tcgtgggagc ttacggggcc aaccaggtgg ctgtgtacag
1441 agctcagcca ctggtgaagg cctctgtcca gctactgggt caagattcac tgaatcctgc
1501 tgtgaagagc tgtgtctac ctcagaccaa gacaccctg agctgcttca acatccagat
1561 gtgtgttgga gccactgggc acaacattcc tcagaagcta tccctaaatg ccgagctgca
1621 gctggaccgg cagaagcccc gccaggggcg gcgggtgctg ctgctgggct ctcaacaggc
1681 aggcaccacc ctgaacctgg atctggggcg aaagcacagc cccatctgcc acaccaccat
1741 ggcttctctt cgagatgagg cagacttccg ggacaagctg agccccattg tgctcagcct
1801 caatgtgtcc ctaccgcccc cggaggctgg aatggccccct gctgtcgtgc tgcattggaga
1861 caccatgtg caggagcaga cactatctgt cctggactct ggggaagatg acgtatgtgt
1921 gccccagctt cagctcactg ccagctgtgac gggctccccg ctctagtgtg gggcagataa
1981 tgtcctggag ctgcagatgg acgcagccaa cgaggcgag ggggcctatg aagcagact
2041 ggccgtgcac ctgccccagg gcgcccacta catgcgggccc ctaagcaatg tcgagggtt
2101 tgagagactc atctgtaatc agaagaagga gaatgagacc aggggtgtgc tgtgtgagct
2161 gggcaacccc atgaagaaga acgcccagat aggaatcgcg atgttggtga gcgtggggaa
2221 tctggaagag gctggggagt ctgtgtcctt ccagctgcag atacggagca agaacagcca
2281 gaatccaaac agcaagattg tgctgtgga cgtgcccgtc cgggcagagg cccaagtgga
2341 gctgcgaggg aactcctttc cagcctccct ggtggtggca gcagaagaag gtgagaggga
2401 gcagaacagc ttggacagct ggggacccaa agtgagcac acctatgagc tccacaacaa
2461 tggccctggg actgtgaatg gtcttcacct cagcatccac cttccgggac agtcccagcc
2521 ctccgacctg ctctacatcc tggatataca gccccagggg ggcttccagt gcttcccaca
2581 gcctcctgtc aacctctca aggtggactg ggggctgccc agc cccagcc cctcccccat
2641 tcaccgggce catcacaagc gggatcgtag acagatcttc ctgccagagc ccgagcagcc
2701 ctcgaggctt caggatccag ttctcgtaag ctgcgactcg gcgcccgtga ctgtggtgca
2761 gtgtgacctg caggagatgg cgcgcgggca cggggccatg gtcacgggtc tggccttctt
2821 gtggctgccc agcctctacc agaggcctct ggatcagttt gtgctgcagt cgcacgcatg
2881 gttcaacgtg tctcctctcc cctatgcggt gccccgctc agcctgcccc gagggggaagc
2941 tcagggtgtg acacagctgc tccgggcctt ggaggagagg gccattccaa tctggtgggt
3001 gctggtgggt gtgctgggtg gcctgctgct gctcaccatc ctggtcctgg ccatgtggaa
3061 ggtcggcttc ttcaagcgga accggccacc cctggaagaa gatgatgaag agggggagtg
3121 atggtgcagc ctacactatt ctagcaggag ggttggcgct gctacctgca ccgccccctc
3181 tccaacaagt tgcctccaag ctttgggttg gagctgttcc attgggtcct cttggtgtcg
3241 tttccctccc aacagagctg ggctaccccc cctcctgctg cctaataaag agactgagcc
3301 ctg

```

Fig. 6

SUBSTITUTE SHEET (RULE 26)

8/8

MARALCPLQALWLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPR  
 TLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHW  
 NVLEKTEEAECTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGA  
 PGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTEYVVG  
 PTWSWTLGAVEILDSYYQRLHRLRAEQMASYFGHSVAVTDVNGDGRHDLVVGAPLYMESRADRKLAEVGRVY  
 LFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDGRGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRS  
 RPSQVLDSPPFTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPVAVKSC  
 VLPQTKTPVSCFNIQMCVGATGHNIPOKLSLNAELQLDRQKPRQGRRVLLLSQQAQGTTLNLDLGGKHSPIC  
 HTTMAFLRDEADFRDKLSPIVLSLNVSLPPTAGMAPAVVLHGDTHVQEQTTRIVLDSGEDDVCVPQLQLTAS  
 VTGSPLLVGADNVLELQMDAANECEGAYEAEALAVHLPQGAHYMRALSNEVEFERLICNQKKENETRVLCEL  
 GNPMMKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVV  
 AAEEGEREQNSLDSWGPKVEHTYELHNNPGTGVNGLHLSIHLPGQSQPSDLLYILDIQPQGGGLQCFPQPPVN  
 PLKVDWGLPIPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGORAMV  
 TVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAPIWVVLVGVLG  
 GLLLLTILVLAMWKVGFFKRNRPPEEDDEEGE

Fig. 7

MARALCPLQALWLEWVLLLLGPCAAPPAWALNLDPVQLTFYAGPNGSQFGFSLDFHKDSHGRVAIVVGAPR  
 TLGPSQEETGGVFLCPWRAEGGQCPSLLFDLRDETRNVGSQTLQTFKARQGLGASVVSWSDVIVACAPWQHW  
 NVLEKTEEAECTPVGSCFLAQPESGRRAEYSPCRGNTLSRIYVENDFSWDKRYCEAGFSSVVTQAGELVLGA  
 PGGYYFLGLLAQAPVADIFSSYRPGILLWHVSSQSLSFDSSNPEYFDGYWGYSVAVGEFDGDLNTEYVVG  
 PTWSWTLGAVEILDSYYQRLHRLRAEQMASYFGHSVAVTDVNGDGRHDLVVGAPLYMESRADRKLAEVGRVY  
 LFLQPRGPHALGAPSLLLTGTQLYGRFGSAIAPLGDLDGRGYNDIAVAAPYGGPSGRGQVLVFLGQSEGLRS  
 RPSQVLDSPPFTGSAFGFSLRGAVDIDDNGYPDLIVGAYGANQVAVYRAQPVVKASVQLLVQDSLNPVAVKSC  
 VLPQTKTPVSCFNIQMCVGATGHNIPOKLSLNAELQLDRQKPRQGRRVLLLSQQAQGTTLNLDLGGKHSPIC  
 HTTMAFLRDEADFRDKLSPIVLSLNVSLPPTAGMAPAVVLHGDTHVQEQTTRIVLDSGEDDVCVPQLQLTAS  
 VTGSPLLVGADNVLELQMDAANECEGAYEAEALAVHLPQGAHYMRALSNEVEFERLICNQKKENETRVLCEL  
 GNPMMKNAQIGIAMLVSVGNLEEAGESVSFQLQIRSKNSQNPNSKIVLLDVPVRAEAQVELRGNSFPASLVV  
 AAEEGEREQNSLDSWGPKVEHTYELHNNPGTGVNGLHLSIHLPGQSQPSDLLYILDIQPQGGGLQCFPQPPVN  
 PLKVDWGLPSPSPSPIHPAHHKRDRRQIFLPEPEQPSRLQDPVLVSCDSAPCTVVQCDLQEMARGORAMV  
 TVLAFLWLPSLYQRPLDQFVLQSHAWFNVSSLPYAVPPLSLPRGEAQVWTQLLRALEERAPIWVVLVGVLG  
 GLLLLTILVLAMWKVGFFKRNRPPEEDDEEGE

Fig. 8

## SEQUENCE LISTING

&lt;110&gt; Nova Molecular, Inc.

<120> METHODS FOR TREATING OR IDENTIFYING A  
 SUBJECT AT RISK FOR A NEUROLOGICAL DISEASE BY DETERMINING  
 THE PRESENCE OF A VARIANT GPIIIA AND/OR VARIANT GPIIB ALLELE

&lt;130&gt; 08523/015WO2

&lt;150&gt; 60/102,624

&lt;151&gt; 1998-10-01

&lt;160&gt; 14

&lt;170&gt; FastSEQ for Windows Version 4.0

&lt;210&gt; 1

&lt;211&gt; 3997

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 1

gcgggaggcg	gacgagatgc	gagcgcggcc	gcggcccccg	ccgctctggg	cgactgtgct	60
ggcgctgggg	gcgctggcgg	gcgttggcgt	aggagggccc	aacatctgta	ccacgcgagg	120
tgtgagctcc	tgccagcagt	gcctggctgt	gagccccatg	tgtgcctggg	gctctgatga	180
ggccctgcct	ctgggctcac	ctcgctgtga	cctgaaggag	aatctgctga	aggataactg	240
tgccccagaa	tccatcgagt	tcccagtgag	tgaggcccca	gtactagagg	acaggcccct	300
cagcgacaag	ggctctggag	acagctccca	ggctactcaa	gtcagtcctc	agaggattgc	360
actccggctc	cggccagatg	attcgaagaa	tttctccatc	caagtgcggc	aggtggagga	420
ttaccctgtg	gacatctact	acttgatgga	cctgtcttac	tccatgaagg	atgatctgtg	480
gagcatccag	aacctgggta	ccaagctggc	caccagatg	cgaaagctca	ccagtaacct	540
gcggattggc	ttcggggcat	ttgtggacaa	gcctgtgtca	ccatacatgt	atatctcccc	600
accagaggcc	ctcgaaaacc	cctgctatga	tatgaagacc	acctgcttgc	ccatgttttg	660
ctacaaacac	gtgctgacgc	taactgacca	ggtagcccg	ttcaatgagg	aagtgaagaa	720
gcagagtgtg	tcacggaacc	gagatgcccc	agaggggtgg	tttgatgcca	tcatgcaggc	780
tacagtctgt	gatgaaaaga	ttggctggag	gaatgatgca	tcccacttgc	tggtgtttac	840
cactgatgcc	aagactcata	tagcattgga	cggaaggctg	gcaggcattg	tccagcctaa	900
tgacgggcag	tgtcatgttg	gtagtgacaa	tcattactct	gcctccacta	ccatggatta	960
tccctctttg	gggctgatga	ctgagaagct	atcccagaaa	aacatcaatt	tgatctttgc	1020
agtgactgaa	aatgtagtca	atctctatca	gaactatagt	gagctcatcc	cagggaccac	1080
agttgggggt	ctgtccatgg	attccagcaa	tgtcctccag	ctcattgttg	atgcttatgg	1140
gaaaatccgt	tctaaagtag	agctggaagt	gcgtgacctc	cctgaagagt	tgtctctatc	1200
cttcaatgcc	acctgcctca	acaatgaggt	catccctggc	ctcaagtctt	gtatgggact	1260
caagattgga	gacacggtga	gcttcagcat	tgaggccaag	gtgcgaggct	gtccccagga	1320
gaaggagaag	tcctttacca	taaagcccgt	gggcttcaag	gacagcctga	tcgtccaggt	1380
cacctttgat	tgtgactgtg	cctgccaggc	ccaagctgaa	cctaatagcc	atcgctgcaa	1440
caatggcaat	gggacctttg	agtgtggggg	atgccgttgt	gggcctggct	ggctgggata	1500
ccagtgtgag	tgctcagagg	aggactatcg	cccttcccag	caggacgaat	gcagcccccg	1560
ggagggctcag	ccgctctgca	gccagcgggg	cgagtgcctc	tgtggtcaat	gtgtctgcca	1620
cagcagtgc	tttggaaga	tcacgggcaa	gtactgcgag	tgtgacgact	tctcctgtgt	1680
ccgctacaag	ggggagatgt	gctcaggcca	tggccagtgc	agctgtgggg	actgcctgtg	1740
tgactccgac	tggaaccggc	actactgcaa	ctgtaccacg	cgtactgaca	cctgcatgtc	1800

atttgaggaa	gaacgcgcc	gagcaaaatg	ggacacagcc	aacaacccac	tgtataaaga	2340
ggccacgtct	accttcacca	atatacagta	ccggggcact	taatgataag	cagtcacct	2400
cagatcatta	tcagcctgtg	ccacgattgc	aggagtcctt	gccatcatgt	ttacagagga	2460
cagtatttgt	ggggagggat	ttggggctca	gagtggggta	ggttgggaga	atgtcagtat	2520
gtggaaagtgt	gggtctgtgt	gtgtgtatgt	gggggtctgt	gtgtttatgt	gtgtgtgttg	2580
tgtgtgggag	tgtgtaattt	aaaattgtga	tgtgtcctga	taagctgagc	tccttagcct	2640
ttgtcccaga	atgcctcctg	cagggattct	tcctgcttag	cttgagggtg	actatggagc	2700
tgagcaggtg	ttcttcatta	cctcagtgag	aagccagctt	tcctcatcag	gccattgtcc	2760
ctgaagagaa	gggcagggtc	gaggcctctc	attccagag	aagggacacc	aagccttggc	2820
tctaccctga	gttcataaat	ttatggttct	caggcctgac	tctcagcagc	tatggtagga	2880
actgctgggc	ttggcagccc	gggtcatctg	tacctctgcc	tcctttcccc	tcctcaggc	2940
cgaaggagga	gtcagggaga	gctgaactat	tagagctgcc	tgtgcctttt	gccatcccct	3000
caaccagagt	atggttctct	cgcaaggga	gtccttgcaa	gctaattctt	tgacctgttg	3060
ggagttagga	tgtctgggcc	actcaggggt	cattcatggc	ctgggggatg	taccagcatc	3120
tcccagttca	taatcacaa	ccttcagatt	tgccttattg	gcagctctac	tctggagggt	3180
tgtttagaag	aagtgtgtca	cccttaggcc	agcaccatct	ctttacctcc	taattccaca	3240
ccctcaagg	agagagtgtc	tgctatgagc	tggggatgtc	tctcatgacc	aaatgctttt	3300
cctcaaagg	agagagtgtc	attgtagagc	cagaggctctg	gccctatgct	tccggcctcc	3360
tgtccctcat	ccatagcacc	tccacatacc	tggccctgag	ccttggtgtg	ctgtatccat	3420
ccatggggct	gattgtattt	accttctacc	tcttggtctg	ccttggaagg	aattattccc	3480
atgagtggc	tggaataaag	tgccaggatg	gaatgatggg	tcagttgtat	cagcacgtgt	3540
ggcgtgttct	tctatgggtt	ggacaacctc	atttcaactc	agtccttaat	ctgagaggtc	3600
acagtgaat	tttattttat	ttttctcatg	atgaggtttt	cttaacttaa	aagaacatgt	3660
atataaacat	gcttgcat	tatttgtaaa	tttatgtgta	tggcaaagaa	ggagagcata	3720
ggaataccaca	cagactggg	cagggtacag	acactccac	ttggcatcat	tcacagcaag	3780
tcactggcca	gtggtggat	ctgtgagggg	ctctctcatg	atagaaggct	atggggatag	3840
atgtgtggac	acattggacc	tttctgagg	aagagggact	gttcttttgt	cccagaaaag	3900
cagtggctcc	attggtgttg	acatacatcc	aacattaaaa	gccaccccca	aatgcccag	3960
aaaaaaagaa	agacttatca	acatttgttc	catgagg			3997

&lt;210&gt; 2

&lt;211&gt; 3997

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

gcgaggaggc	gacgagatgc	gagcgcgccc	gcgcccccg	ccgctctggg	cgactgtgct	60
ggcgctgggg	gcgctggcgg	gcgttggcgt	aggagggcc	aacatctgta	ccacgcgagg	120
tgtgagctcc	tgccagcagt	gcctggctgt	gagcccatg	tgtgcctggg	gctctgatga	180
ggccctgcct	ccgggtcac	ctcgctgtga	cctgaaggag	aatctgctga	aggataactg	240
tgccccagaa	tccatcgagt	tcccagttag	tgaggcccg	gtactagagg	acaggcccct	300
cagcgacaag	ggctctggag	acagctccca	ggtcactcaa	gtcagtcacc	agaggattgc	360
actccggctc	cggccagatg	attcgaagaa	tttctccatc	caagtgcggc	aggtggagg	420
ttaccctgtg	gacatctact	acttgatgga	cctgtcttac	tccatgaagg	atgatctgtg	480
gagcatccag	aacctgggta	ccaagctggc	caccagatg	cgaaagctca	ccagtaacct	540
gcggattggc	ttcggggcat	ttgtggacaa	gcctgtgtca	ccatacatgt	atatctcccc	600
accagaggcc	ctcgaaaacc	cctgctatga	tatgaagacc	acctgcttgc	ccatgttttg	660
ctacaaacac	gtgctgacgc	taactgacca	ggtgaccgc	ttcaatgagg	aagtgaagaa	720
gcagagtgtg	tcacggaaacc	gagatgcccc	agagggtggc	tttgatgcca	tcatgcaggc	780
tacagctctg	gatgaaaaga	ttggctggag	gaatgatgca	tcccacttgc	tggtgtttac	840
cactgatgcc	aagactcata	tagcattgga	cggaaggctg	gcaggcattg	tccagcctaa	900
tgacgggcag	tgtcatgttg	gtagtacaa	tcattactct	gcctccacta	ccatggatta	960
tccctctttg	gggctgatga	ctgagaagct	atcccagaaa	aacatcaatt	tgatctttgc	1020
agtgaactgaa	aatgtagtca	atctctatca	gaactatagt	gagctcatcc	cagggaccac	1080
agttgggggt	ctgtccatgg	attccagcaa	tgtcctccag	ctcattgttg	atgcttatgg	1140
gaaaatccgt	tctaaagtag	agctggaagt	gcgtgacctc	cctgaagagt	tgtctctatc	1200
cttcaatgcc	acctgcctca	acaatgaggt	catccctggc	ctcaagtctt	gtatgggact	1260
caagattgga	gacacgggtg	gcttcagcat	tgaggccaag	gtgcgaggct	gtccccagga	1320
gaaggagaag	tcctttacca	taaagccgtg	gggcttcaag	gacagctga	tgcgccaggt	1380
cacctttgat	tgtgactgtg	cctgccaggc	ccaagtga	cctaatagcc	atcgctgcaa	1440
caatggcaat	gggacctttg	agtgtgggg	atgccgttgt	gggcctggct	ggctgggatc	1500
ccagtgtgag	tgtcagagg	aggactatcg	cccttcccag	caggacgaat	gcagcccccg	1560
ggagggtcag	cccgtctgca	gccagcgggg	cgagtgcctc	tgtggtcaat	gtgtctgcca	1620



```

cagcagtgc tttggcaaga tcacgggcaa gtactgcgag tgtgacgact tctcctgtgt 1680
ccgctacaag ggggagatgt gctcaggcca tggccagtgc agctgtgggg actgcctgtg 1740
tgactccgac tggaccggct actactgcaa ctgtaccacg cgtactgaca cctgcatgtc 1800
cagcaatggg ctgctgtgca gcggcccgcg caagtgtgaa tgtggcagct gtgtctgtat 1860
ccagccgggc tccatgggg acacctgtga gaagtgcgcc acctgcccag atgcctgcac 1920
ctttaagaaa gaatgtgtgg agtgaagaa gtttgaccgg gagccctaca tgaccgaaaa 1980
tacctgaac cgttactgcc gtgacgagat tgagtcagtg aaagagctta aggacactgg 2040
caaggatgca gtgaattgta cctataagaa tgaggatgac tgtgtcgtca gattccagta 2100
ctatgaagat tctagtggaa agtccatcct gtatgtggta gaagagccag agtgtcccaa 2160
gggccctgac atcctggtgg tccctgctctc agtgcctggg gccattctgc tcattggcct 2220
tgccgcccctg ctcatctgga aactcctcat caccatccac gaccgaaaag aattcgctaa 2280
at ttgaggaa gaacgcgcca gagcaaaatg ggacacagcc aacàaccac tgtataaaga 2340
ggccacgtct accttcacca atatcacgta ccggggcact taatgataag cagtcatcct 2400
cagatcatta tcagcctgtg ccacgattgc agtgatccct gccatcatgt ttacagagga 2460
cagtatttgt ggggagggat ttggggctca gagtggggta gggtgggaga atgtcagtat 2520
gtggaagtgt gggctctgtgt gtgtgtatgt gggggctctgt gtgtttatgt gtgtgtgtg 2580
tgtgtgggag tgtgtaattt aaaattgtga tgtgtcctga taagctgagc tccttagcct 2640
ttgtcccaga ttgcctcctg cagggattct tccctgctag cttagagggtg actatggagc 2700
tgagcaggtg ttcttcatta cctcagttag aagccagctt tcctcatcag gccattgtcc 2760
ctgaagagaa gggcagggct gaggcctctc attccagagg aagggaacac aagccttggc 2820
tctaccctga gttcataaat ttatggttct caggcctgac tctcagcagc tatggttagga 2880
actgctcctga ttggcagccc gggctcatctg tagagctgcc tgtgcctttt gccatccct 2940
cgaaggagga gtcagggaga gctgaactat tagagctgcc tgtgcctttt gccatccct 3000
caaccagct atggttctct cgcaaggga gtccttgcaa gctaattctt tgacctgttg 3060
ggagttagga tgtctgggcc actcaggggt cattcatggc ctgggggatg taccagcatc 3120
tccccttca taatcacac ccttcagatt tgccttattg gcagctctac tctggagggt 3180
tgtttagaag aagtgtgtca cccttaggcc agcaccatct cttacacctc taattccaca 3240
ccctcactgc tgtagacatt tgctatgagc tggggatgtc tctcatgacc aaatgctttt 3300
cctcaaaggg agagagtgtc attgtagagc cagaggtctg gccctatgct tccggcctcc 3360
tgtcctcat ccatagcacc tccacatacc tggccctgag ccttgggtgtg ctgtatccat 3420
ccatggggct gattgtattt accttctacc tcttggctgc cttgtgaagg aattattccc 3480
atgagttggc tgggaataag tgccaggatg gaatgatggg tcagttgtat cagcacgtgt 3540
ggcctgttct tctatgggtt ggacaacctc attttaactc agtctttaat ctgagaggcc 3600
acagtgcatt tttatttat ttttctcat atgaggtttt ctttaactta aagaacatgt 3660
atataaacat gcttgcatca tatttgaata tttatgtgta tggcaaagaa ggagagcata 3720
ggaaaccaca cagacttggg cagggtacag acactccac ttggcatcat tcacagcaag 3780
tcaactggcca gtggctggat ctgtgagggg ctctctcatg atagaaggct atggggatag 3840
atgtgtggac acattggacc tttcctgagg aagagggact gttcttttgt cccagaaaag 3900
cagtggctcc attggtgttg acatacatcc aacattaaaa gccaccccca aatgcccaag 3960
aaaaaaagaa agacttatca acatttgttc catgagg 3997

```

<210> 3  
 <211> 788  
 <212> PRT  
 <213> Homo sapiens

<400> 3  
 Met Arg Ala Arg Pro Arg Pro Arg Pro Leu Trp Val Thr Val Leu Ala  
 1 5 10 15  
 Leu Gly Ala Leu Ala Gly Val Gly Val Gly Gly Pro Asn Ile Cys Thr  
 20 25 30  
 Thr Arg Gly Val Ser Ser Cys Gln Gln Cys Leu Ala Val Ser Pro Met  
 35 40 45  
 Cys Ala Trp Cys Ser Asp Glu Ala Leu Pro Leu Gly Ser Pro Arg Cys  
 50 55 60  
 Asp Leu Lys Glu Asn Leu Leu Lys Asp Asn Cys Ala Pro Glu Ser Ile  
 65 70 75 80  
 Glu Phe Pro Val Ser Glu Ala Arg Val Leu Glu Asp Arg Pro Leu Ser  
 85 90 95  
 Asp Lys Gly Ser Gly Asp Ser Ser Gln Val Thr Gln Val Ser Pro Gln  
 100 105 110  
 Arg Ile Ala Leu Arg Leu Arg Pro Asp Asp Ser Lys Asn Phe Ser Ile  
 115 120 125

Gln Val Arg Gln Val Glu Asp Tyr Pro Val Asp Ile Tyr Tyr Leu Met  
 130 135 140  
 Asp Leu Ser Tyr Ser Met Lys Asp Asp Leu Trp Ser Ile Gln Asn Leu  
 145 150 155 160  
 Gly Thr Lys Leu Ala Thr Gln Met Arg Lys Leu Thr Ser Asn Leu Arg  
 165 170 175  
 Ile Gly Phe Gly Ala Phe Val Asp Lys Pro Val Ser Pro Tyr Met Tyr  
 180 185 190  
 Ile Ser Pro Pro Glu Ala Leu Glu Asn Pro Cys Tyr Asp Met Lys Thr  
 195 200 205  
 Thr Cys Leu Pro Met Phe Gly Tyr Lys His Val Leu Thr Leu Thr Asp  
 210 215 220  
 Gln Val Thr Arg Phe Asn Glu Glu Val Lys Lys Gln Ser Val Ser Arg  
 225 230 235 240  
 Asn Arg Asp Ala Pro Glu Gly Gly Phe Asp Ala Ile Met Gln Ala Thr  
 245 250 255  
 Val Cys Asp Glu Lys Ile Gly Trp Arg Asn Asp Ala Ser His Leu Leu  
 260 265 270  
 Val Phe Thr Thr Asp Ala Lys Thr His Ile Ala Leu Asp Gly Arg Leu  
 275 280 285  
 Ala Gly Ile Val Gln Pro Asn Asp Gly Gln Cys His Val Gly Ser Asp  
 290 295 300  
 Asn His Tyr Ser Ala Ser Thr Thr Met Asp Tyr Pro Ser Leu Gly Leu  
 305 310 315 320  
 Met Thr Glu Lys Leu Ser Gln Lys Asn Ile Asn Leu Ile Phe Ala Val  
 325 330 335  
 Thr Glu Asn Val Val Asn Leu Tyr Gln Asn Tyr Ser Glu Leu Ile Pro  
 340 345 350  
 Gly Thr Thr Val Gly Val Leu Ser Met Asp Ser Ser Asn Val Leu Gln  
 355 360 365  
 Leu Ile Val Asp Ala Tyr Gly Lys Ile Arg Ser Lys Val Glu Leu Glu  
 370 375 380  
 Val Arg Asp Leu Pro Glu Glu Leu Ser Leu Ser Phe Asn Ala Thr Cys  
 385 390 395 400  
 Leu Asn Asn Glu Val Ile Pro Gly Leu Lys Ser Cys Met Gly Leu Lys  
 405 410 415  
 Ile Gly Asp Thr Val Ser Phe Ser Ile Glu Ala Lys Val Arg Gly Cys  
 420 425 430  
 Pro Gln Glu Lys Glu Lys Ser Phe Thr Ile Lys Pro Val Gly Phe Lys  
 435 440 445  
 Asp Ser Leu Ile Val Gln Val Thr Phe Asp Cys Asp Cys Ala Cys Gln  
 450 455 460  
 Ala Gln Ala Glu Pro Asn Ser His Arg Cys Asn Asn Gly Asn Gly Thr  
 465 470 475 480  
 Phe Glu Cys Gly Val Cys Arg Cys Gly Pro Gly Trp Leu Gly Ser Gln  
 485 490 495  
 Cys Glu Cys Ser Glu Glu Asp Tyr Arg Pro Ser Gln Gln Asp Glu Cys  
 500 505 510  
 Ser Pro Arg Glu Gly Gln Pro Val Cys Ser Gln Arg Gly Glu Cys Leu  
 515 520 525  
 Cys Gly Gln Cys Val Cys His Ser Ser Asp Phe Gly Lys Ile Thr Gly  
 530 535 540  
 Lys Tyr Cys Glu Cys Asp Asp Phe Ser Cys Val Arg Tyr Lys Gly Glu  
 545 550 555 560  
 Met Cys Ser Gly His Gly Gln Cys Ser Cys Gly Asp Cys Leu Cys Asp  
 565 570 575  
 Ser Asp Trp Thr Gly Tyr Tyr Cys Asn Cys Thr Thr Arg Thr Asp Thr  
 580 585 590  
 Cys Met Ser Ser Asn Gly Leu Leu Cys Ser Gly Arg Gly Lys Cys Glu  
 595 600 605  
 Cys Gly Ser Cys Val Cys Ile Gln Pro Gly Ser Tyr Gly Asp Thr Cys  
 610 615 620  
 Glu Lys Cys Pro Thr Cys Pro Asp Ala Cys Thr Phe Lys Lys Glu Cys

625 630 635 640  
 Val Glu Cys Lys Lys Phe Asp Arg Glu Pro Tyr Met Thr Glu Asn Thr  
 Cys Asn Arg Tyr 645 Cys Arg Asp Glu Ile Glu Ser Val Lys Glu Leu Lys  
 Asp Thr Gly Lys Asp Ala Val Asn Cys Thr Tyr Lys Asn Glu Asp Asp  
 Cys Val Val Arg Phe Gln Tyr Tyr Glu Asp Ser Ser Gly Lys Ser Ile  
 Leu Tyr Val Val Glu Glu Pro Glu Cys Pro Lys Gly Pro Asp Ile Leu  
 705 710 715 720  
 Val Val Leu Leu Ser Val Met Gly Ala Ile Leu Leu Ile Gly Leu Ala  
 Ala Leu Leu Ile Trp Lys Leu Leu Ile Thr Ile His Asp Arg Lys Glu  
 Phe Ala Lys Phe Glu Glu Glu Arg Ala Arg Ala Lys Trp Asp Thr Ala  
 Asn Asn Pro Leu Tyr Lys Glu Ala Thr Ser Thr Phe Thr Asn Ile Thr  
 Tyr Arg Gly Thr  
 785

<210> 4  
 <211> 788  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Met Arg Ala Arg Pro Arg Pro Arg Pro Leu Trp Val Thr Val Leu Ala  
 1 5 10 15  
 Leu Gly Ala Leu Ala Gly Val Gly Val Gly Gly Pro Asn Ile Cys Thr  
 20 25 30  
 Thr Arg Gly Val Ser Ser Cys Gln Gln Cys Leu Ala Val Ser Pro Met  
 35 40 45  
 Cys Ala Trp Cys Ser Asp Glu Ala Leu Pro Pro Gly Ser Pro Arg Cys  
 50 55 60  
 Asp Leu Lys Glu Asn Leu Leu Lys Asp Asn Cys Ala Pro Glu Ser Ile  
 65 70 75 80  
 Glu Phe Pro Val Ser Glu Ala Arg Val Leu Glu Asp Arg Pro Leu Ser  
 85 90 95  
 Asp Lys Gly Ser Gly Asp Ser Ser Gln Val Thr Gln Val Ser Pro Gln  
 100 105 110  
 Arg Ile Ala Leu Arg Leu Arg Pro Asp Asp Ser Lys Asn Phe Ser Ile  
 115 120 125  
 Gln Val Arg Gln Val Glu Asp Tyr Pro Val Asp Ile Tyr Tyr Leu Met  
 130 135 140  
 Asp Leu Ser Tyr Ser Met Lys Asp Asp Leu Trp Ser Ile Gln Asn Leu  
 145 150 155 160  
 Gly Thr Lys Leu Ala Thr Gln Met Arg Lys Leu Thr Ser Asn Leu Arg  
 165 170 175  
 Ile Gly Phe Gly Ala Phe Val Asp Lys Pro Val Ser Pro Tyr Met Tyr  
 180 185 190  
 Ile Ser Pro Pro Glu Ala Leu Glu Asn Pro Cys Tyr Asp Met Lys Thr  
 195 200 205  
 Thr Cys Leu Pro Met Phe Gly Tyr Lys His Val Leu Thr Leu Thr Asp  
 210 215 220  
 Gln Val Thr Arg Phe Asn Glu Glu Val Lys Lys Gln Ser Val Ser Arg  
 225 230 235 240  
 Asn Arg Asp Ala Pro Glu Gly Gly Phe Asp Ala Ile Met Gln Ala Thr  
 245 250 255  
 Val Cys Asp Glu Lys Ile Gly Trp Arg Asn Asp Ala Ser His Leu Leu  
 260 265 270  
 Val Phe Thr Thr Asp Ala Lys Thr His Ile Ala Leu Asp Gly Arg Leu

275 280 285  
 Ala Gly Ile Val Gln Pro Asn Asp Gly Gln Cys His Val Gly Ser Asp  
 290 295 300  
 Asn His Tyr Ser Ala Ser Thr Thr Met Asp Tyr Pro Ser Leu Gly Leu  
 305 310 315 320  
 Met Thr Glu Lys Leu Ser Gln Lys Asn Ile Asn Leu Ile Phe Ala Val  
 325 330 335  
 Thr Glu Asn Val Val Asn Leu Tyr Gln Asn Tyr Ser Glu Leu Ile Pro  
 340 345 350  
 Gly Thr Thr Val Gly Val Leu Ser Met Asp Ser Ser Asn Val Leu Gln  
 355 360 365  
 Leu Ile Val Asp Ala Tyr Gly Lys Ile Arg Ser Lys Val Glu Leu Glu  
 370 375 380  
 Val Arg Asp Leu Pro Glu Glu Leu Ser Leu Ser Phe Asn Ala Thr Cys  
 385 390 395 400  
 Leu Asn Asn Glu Val Ile Pro Gly Leu Lys Ser Cys Met Gly Leu Lys  
 405 410 415  
 Ile Gly Asp Thr Val Ser Phe Ser Ile Glu Ala Lys Val Arg Gly Cys  
 420 425 430  
 Pro Gln Glu Lys Glu Lys Ser Phe Thr Ile Lys Pro Val Gly Phe Lys  
 435 440 445  
 Asp Ser Leu Ile Val Gln Val Thr Phe Asp Cys Asp Cys Ala Cys Gln  
 450 455 460  
 Ala Gln Ala Glu Pro Asn Ser His Arg Cys Asn Asn Gly Asn Gly Thr  
 465 470 475 480  
 Phe Glu Cys Gly Val Cys Arg Cys Gly Pro Gly Trp Leu Gly Ser Gln  
 485 490 495  
 Cys Glu Cys Ser Glu Glu Asp Tyr Arg Pro Ser Gln Gln Asp Glu Cys  
 500 505 510  
 Ser Pro Arg Glu Gly Gln Pro Val Cys Ser Gln Arg Gly Glu Cys Leu  
 515 520 525  
 Cys Gly Gln Cys Val Cys His Ser Ser Asp Phe Gly Lys Ile Thr Gly  
 530 535 540  
 Lys Tyr Cys Glu Cys Asp Asp Phe Ser Cys Val Arg Tyr Lys Gly Glu  
 545 550 555 560  
 Met Cys Ser Gly His Gly Gln Cys Ser Cys Gly Asp Cys Leu Cys Asp  
 565 570 575  
 Ser Asp Trp Thr Gly Tyr Tyr Cys Asn Cys Thr Thr Arg Thr Asp Thr  
 580 585 590  
 Cys Met Ser Ser Asn Gly Leu Leu Cys Ser Gly Arg Gly Lys Cys Glu  
 595 600 605  
 Cys Gly Ser Cys Val Cys Ile Gln Pro Gly Ser Tyr Gly Asp Thr Cys  
 610 615 620  
 Glu Lys Cys Pro Thr Cys Pro Asp Ala Cys Thr Phe Lys Lys Glu Cys  
 625 630 635 640  
 Val Glu Cys Lys Lys Phe Asp Arg Glu Pro Tyr Met Thr Glu Asn Thr  
 645 650 655  
 Cys Asn Arg Tyr Cys Arg Asp Glu Ile Glu Ser Val Lys Glu Leu Lys  
 660 665 670  
 Asp Thr Gly Lys Asp Ala Val Asn Cys Thr Tyr Lys Asn Glu Asp Asp  
 675 680 685  
 Cys Val Val Arg Phe Gln Tyr Tyr Glu Asp Ser Ser Gly Lys Ser Ile  
 690 695 700  
 Leu Tyr Val Val Glu Glu Pro Glu Cys Pro Lys Gly Pro Asp Ile Leu  
 705 710 715 720  
 Val Val Leu Leu Ser Val Met Gly Ala Ile Leu Leu Ile Gly Leu Ala  
 725 730 735  
 Ala Leu Leu Ile Trp Lys Leu Leu Ile Thr Ile His Asp Arg Lys Glu  
 740 745 750  
 Phe Ala Lys Phe Glu Glu Glu Arg Ala Arg Ala Lys Trp Asp Thr Ala  
 755 760 765  
 Asn Asn Pro Leu Tyr Lys Glu Ala Thr Ser Thr Phe Thr Asn Ile Thr  
 770 775 780

Tyr Arg Gly Thr  
785

<210> 5  
<211> 3303  
<212> DNA  
<213> Homo sapiens

<400> 5

gatggccaga	gctttgtgtc	cactgcaagc	cctctggcctt	ctggagtggg	tgtctgtgct	60
cttgggacct	tgtgctgccc	ctccagcctg	ggccttgaac	ctggacccag	tgcagctcac	120
cttctatgca	ggccccaatg	gcagccagtt	tggattttca	ctggacttcc	acaaggacag	180
ccatgggaga	gtggccatcg	tgggtggcgc	cccgcggacc	ctgggcccga	gccaggagga	240
gacggggcgc	gtgttcctgt	gcccctggag	ggccgagggc	ggccagtgcc	cctcgctgct	300
ctttgacctc	cgtgatgaga	cccgaatgt	aggctcccaa	actttacaaa	ccttcaaggc	360
ccgccaaagga	ctgggggctg	cggctcgtcag	ctggagcgac	gtcattgtgg	cctgcgcccc	420
ctggcagcac	tggaaacgtcc	tagaaaagac	tgaggaggct	gagaagacgc	ccgtaggtag	480
ctgctttttg	gtcagccag	agagcggccg	ccgcgcccag	tactccccct	gtcgcgggaa	540
caccctgagc	cgcattttacg	tggaaaatga	ttttagctgg	gacaagcggt	actgtgaagc	600
gggcttcagc	tccgtgggtca	ctcaggccgg	agagctggtg	cttggggctc	ctggcgggcta	660
ttatttctta	ggtctcctgg	cccaggctcc	agttgcggat	attttctcga	gttaccgccc	720
aggcatcctt	ttgtggcacg	tgtctcccca	gagcctctcc	tttgactcca	gcaaccaga	780
gtacttcgac	ggctactggg	ggtactcggg	ggcctggggc	gagttcgacg	gggatctcaa	840
cactacagaa	tatgtcgtcg	gtgccccac	ttggagctgg	accctgggag	cgggtggaat	900
tttgattctt	tactaccaga	ggctgcacg	gctgcgcgca	gagcagatgg	cgtcgtattt	960
tgggcattca	gtgggtgtca	ctgacgtcaa	cggggatggg	aggcatgac	tgtgtgtggg	1020
cgctccactg	tatatggaga	gccgggcaga	ccgaaaactg	gccgaagtgg	ggcgtgtgta	1080
tttgttcctg	cagccgcgag	gccccacgc	gctgggtgcc	cccagcctcc	tgtgactgg	1140
cacacagctc	tatgggcgat	tcggctctgc	catcgacccc	ctgggcgacc	tcgaccggga	1200
tggctaccaat	gacattcgag	tggtgcctcc	ctacgggggt	cccagtggcc	ggggccaagt	1260
gctgggtgtt	ctgggtcaga	gtgaggggct	gaggtcacgt	ccctcccagg	tcctggacag	1320
ccccttcccc	acaggctctg	cctttggcct	ctcccttcga	ggtgccgtag	acatcgatga	1380
caacggatac	ccagacctga	tcgtgggagc	ttacggggcc	aaccaggtgg	ctgtgtacag	1440
agctacacca	gtggtgaagg	cctctgtcca	gctactggtg	caagattcac	tgaatcctgc	1500
tgtgaagagc	tgtgtcctac	ctcagaccaa	gacacccgtg	agctgcttca	acatccagat	1560
gtgtgttgga	gccactgggc	acaacattcc	tcagaagcta	tccctaaatg	ccgagctgca	1620
gctggaccgg	cagaagcccc	gccaggggcg	gcgggtgctg	ctgctgggct	ctcaacaggc	1680
aggcaccagc	ctgaacctgg	atctggcg	aaagcacagc	cccactctgc	acaccaccat	1740
ggccttccct	cgagatgagg	cagacttccg	ggacaagctg	agccccattg	tgtcagcct	1800
caatgtgtcc	ctaccgcccc	cggaggctgg	aatggccctt	gctgtcgtgc	tgcattggaga	1860
cacccatgtg	caggagcaga	cacgaatcgt	cctggactct	ggggaagatg	acgtatgtgt	1920
gccccagctt	cagctcaactg	ccagcgtgac	gggctccccg	ctcctagtgt	gggcagataa	1980
tgtcctggag	ctgcagatgg	acgcagccaa	cgagcccgag	ggggcctatg	aagcagagca	2040
ggcctgtcac	ctgccccagg	gcgcccacta	catgcggggc	ctaagcaatg	tcgagggtct	2100
tgagagactc	atctgtaatc	agaagaagga	gaatgagacc	agggtggtgc	tgtgtgagct	2160
gggcaacccc	atgaagaaga	acgcccagat	aggaatcgcg	atgttggtga	gcgtggggaa	2220
tctggaagag	gctggggagt	ctgtgtcctt	ccagctgcag	atacgagca	agaacagcca	2280
gaatccaaac	agcaagattg	tgtgtgtgga	cgtgccggtc	cgggcagagg	cccaagtggg	2340
gctgcgaggg	aactcctttc	cagcctccct	ggtggtggca	gcagaagaag	gtgagaggga	2400
gcagaacagc	ttggacagct	ggggacccaa	agtggagcac	acctatgagc	tccacaacaa	2460
tggccctggg	actgtgaatg	gtcttcacct	cagcatccac	cttccgggac	agtcacagcc	2520
ctccgacctg	ctctacatcc	tggatataca	gccccagggg	ggccttcagt	gcttcccaca	2580
gcctcctgtc	aaccctctca	agggtggaactg	ggggctgccc	atccccagcc	cctcccccat	2640
tcacccggcc	catcacaagc	gggatcgag	acagatcttc	ctgccagagc	ccgagcagcc	2700
ctcgaggctt	caggatccag	ttctcgtaag	ctgcgactcg	gcgcccgtga	ctgtggtgca	2760
gtgtgacctg	caggagatgg	cgcgcgggca	gcgggccatg	gtcacgggtg	tggccttct	2820
gtggctgccc	agcctctacc	agaggcctct	ggatcagttt	gtgctgcagt	cgcacgcatg	2880
gttcaacgtg	tctccctccc	cctatgcggt	gccccgcctc	agcctgcccc	gaggggaagc	2940
tcaggtgtgg	acacagctgc	tccgggctt	ggaggagagg	gccattccaa	tctggtgggt	3000
gctgggtggg	gtgctgggtg	gcctgctgct	gctcaccatc	ctggtcctgg	ccatgtggaa	3060
ggtcggcttc	ttcaagcgga	accggccacc	cctggaagaa	gatgatgaag	agggggagtg	3120
atggtgcagc	ctacactatt	ctagcaggag	ggttgggctg	gctacctgca	ccgccccctc	3180
tccaacaagt	tgccctcaag	ctttgggttg	gagctgttcc	attgggtcct	cttgggtgtg	3240

tttccctccc aacagagctg ggctaccccc cctcctgctg cctaataaag agactgagcc 3300  
ctg 3303

<210> 6  
<211> 3303  
<212> DNA  
<213> Homo sapiens

<400> 6  
gatggccaga gctttgtgtc cactgcaagc cctctggctt ctggagtggg tgctgctgct 60  
cttgggacct tgtgctgccc ctccagcctg ggccttgaac ctggaccagc tgcagctcac 120  
cttctatgca ggccccaatg gcagccagtt tggattttca ctggacttcc acaaggacag 180  
ccatgggaga gtggccatcg tgggtggcgc ccgcgggacc ctgggccccca gccaggagga 240  
gacggggcggc gtgttcctgt gccctggag ggccagtgcc cctcgctgct 300  
ctttgacctc cgtgatgaga cccgaaatgt aggtcccaa actttacaaa ccttcaaggc 360  
ccgccaagga ctgggggctg cggctcgtcag ctggagcgac gtcattgtgg cctgcgcccc 420  
ctggcagcac tggaaagctc tagaaaagac tgaggaggct gagaagacgc ccgtaggtag 480  
ctgctttttg tctcagccag agagcggccg ccgcggcgag tactccccct gtcgcgggaa 540  
caccctgagc cgcatttacg tggaaaatga ttttagctgg gacaagcgtt actgtgaagc 600  
gggcttcagc tccgtgggca ctcaggcccg agagctgggtg cttggggctc ctggcggtta 660  
ttatttctta ggtctcctgg cccaggctcc agttgcggat attttctcga gttaccgccc 720  
aggcatcctt ttgtggcaag tgtcctccca gacgtctccc tttgactcca gcaaccagca 780  
gtacttcgac ggctactggg ggtactcggg ggccgtgggc gagttcgacg gggatctcaa 840  
cactacagaa tatgtcgtcg gtgccccac ttggagctgg accctgggag cgggtggaaat 900  
tttgatttcc tactaccaga ggctgcacg gctgcgcgca gagcagatgg cgtcgtatgt 960  
tgggcattca gtggctgtca ctgacgtcaa cggggatggg aggcattgat tgctgggtggg 1020  
cgctccactg tatatggaga gccgggcaga ccgaaaactg gccgaagtgg ggctgtgta 1080  
tttgttcctg cagccgcgag gcccccacgc gctgggtgcc cccagcctcc tgctgactgg 1140  
cacacagctc tatgggcatg tcggctctgc catcgacccc ctgggcgacc tcgaccggga 1200  
tggtacaaat gacattgcag tggctgcccc ctacgggggt cccagtggcc ggggccaagt 1260  
gctgggtgtc ctgggtcaga gtgaggggct gaggtcacgt cctcccagg tcctggacag 1320  
ccccttcccc acaggtctctg cctttggctt ctcccttcga ggtgccgtag acatcgatga 1380  
caacggatac ccagacctga tctgtgggag ttacggggcc aaccagggtg ctgtgtacag 1440  
agctacacca gtggtgaagg cctctgtcca gctactgtg caagattcac tgaatcctgc 1500  
tgtgaagagc tgtgtcctac ctcagaccaa gacaccctg agctgcttca acatccagat 1560  
gtgtgttggg gccactgggc acaacattcc tcagaagcta tccctaaatg ccgagctgca 1620  
gctggaccgg cagaagcccc gccaggggccg gcgggtgctg ctgctgggct ctcaacaggc 1680  
aggcaccacc ctgaacctgg atctgggcgg aaagcacagc cccatctgcc acaccaccat 1740  
ggccttcctt cgagatgagg cagacttccg ggacaagctg agccccattg tgctcagcct 1800  
caatgtgtcc ctaccgcccc cggaggctgg aatggccctt gctgtcgtgc tgcattggaga 1860  
caccatgtg caggagcaga caccgaatcgt cctggactct ggggaagatg acgtatgtgt 1920  
gccccagctt cagctcactg ccagcgtgac gggtcccccg ctccctagtgt gggcagataa 1980  
tgtcctggag ctgcagatgg acgcagccaa cgagggcgag ggggcctatg aagcagagct 2040  
ggccgtgcac ctgccccagg gcgcccacta catgcgggcc ctaagcaatg tcgagggtct 2100  
tgagagactc atctgtaatc agaagaagga gaatgagacc aggggtggtg tgtgtgagct 2160  
gggcaacccc atgaagaaga acgcccagat aggaatcgcg atgttggtga gcgtggggaa 2220  
tctggaagag gctggggagt ctgtgtcctt ccagctgcag atacggagca agaacagcca 2280  
gaatccaaac agcaagattg tgcgtgtgga cgtgccggtc cgggcagagg cccaagtgga 2340  
gctgcgaggg aactcctttc cagcctccct ggtgtgtgca gcagaagaag gtgagaggga 2400  
gcagaacagc ttggacagct ggggacccaa agtggagcac acctatgagc tccacaacaa 2460  
tggcctggg actgtgaatg gtcttcacct cagcatccac cttccgggac agtcccagcc 2520  
ctccgacctg ctctacatcc tggatataca gccccagggg ggccttcagt gcttcccaca 2580  
gcctcctgtc aacctctca aggtggactg ggggtgccc agccccagcc cctcccccat 2640  
tcaccgggcc catcacaagc gggatcgag acagatcttc ctgccagagc ccgagcagcc 2700  
ctcgaggctt caggatccag ttctcgtaag ctgcgactcg gcgcctgta ctgtgtgca 2760  
gtgtgacctg caggagatgg cgcgcgggca ggcggccatg gtcacggtgc tggccttcc 2820  
gtggctgccc agcctctacc agaggcctct ggatcagttt gtgctgcagt cgcacgcatg 2880  
gttcaacgtg tccctccctc cctatgcggt gcccccgtc agcctgcccc gaggggaagc 2940  
tcaggtgtgg acacaggtg tccgggcctt ggaggagagg gccattccaa tctggtgggt 3000  
gctgggtgggt gtgctgggtg gectgtcttc gctcaccatc ctggtcctgg ccatgtgaa 3060  
ggtcggcttc ttcaagcgga accggc acc cctggaagaa gatgatgaag agggggagtg 3120  
atggtgcagc ctacactatt ctacg gag ggttgggctg gctacctga ccgccccctc 3180  
tccaacaagt tgccctcaag ctttctgtt gagctgttcc attgggtcct cttggtgtcg 3240

tttccctccc aacagagctg ggctaccccc cctcctgctg cctaataaag agactgagcc  
ctg

3300

3303

&lt;210&gt; 7

&lt;211&gt; 1039

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

Met Ala Arg Ala Leu Cys Pro Leu Gln Ala Leu Trp Leu Leu Glu Trp  
1 5 10 15  
Val Leu Leu Leu Gly Pro Cys Ala Ala Pro Pro Ala Trp Ala Leu  
20 25 30  
Asn Leu Asp Pro Val Gln Leu Thr Phe Tyr Ala Gly Pro Asn Gly Ser  
35 40 45  
Gln Phe Gly Phe Ser Leu Asp Phe His Lys Asp Ser His Gly Arg Val  
50 55 60  
Ala Ile Val Val Gly Ala Pro Arg Thr Leu Gly Pro Ser Gln Glu Glu  
65 70 75 80  
Thr Gly Gly Val Phe Leu Cys Pro Trp Arg Ala Glu Gly Gly Gln Cys  
85 90 95  
Pro Ser Leu Leu Phe Asp Leu Arg Asp Glu Thr Arg Asn Val Gly Ser  
100 105 110  
Gln Thr Leu Gln Thr Phe Lys Ala Arg Gln Gly Leu Gly Ala Ser Val  
115 120 125  
Val Ser Trp Ser Asp Val Ile Val Ala Cys Ala Pro Trp Gln His Trp  
130 135 140  
Asn Val Leu Glu Lys Thr Glu Glu Ala Glu Lys Thr Pro Val Gly Ser  
145 150 155 160  
Cys Phe Leu Ala Gln Pro Glu Ser Gly Arg Arg Ala Glu Tyr Ser Pro  
165 170 175  
Cys Arg Gly Asn Thr Leu Ser Arg Ile Tyr Val Glu Asn Asp Phe Ser  
180 185 190  
Trp Asp Lys Arg Tyr Cys Glu Ala Gly Phe Ser Ser Val Val Thr Gln  
195 200 205  
Ala Gly Glu Leu Val Leu Gly Ala Pro Gly Gly Tyr Tyr Phe Leu Gly  
210 215 220  
Leu Leu Ala Gln Ala Pro Val Ala Asp Ile Phe Ser Ser Tyr Arg Pro  
225 230 235 240  
Gly Ile Leu Leu Trp His Val Ser Ser Gln Ser Leu Ser Phe Asp Ser  
245 250 255  
Ser Asn Pro Glu Tyr Phe Asp Gly Tyr Trp Gly Tyr Ser Val Ala Val  
260 265 270  
Gly Glu Phe Asp Gly Asp Leu Asn Thr Thr Glu Tyr Val Val Gly Ala  
275 280 285  
Pro Thr Trp Ser Trp Thr Leu Gly Ala Val Glu Ile Leu Asp Ser Tyr  
290 295 300  
Tyr Gln Arg Leu His Arg Leu Arg Ala Glu Gln Met Ala Ser Tyr Phe  
305 310 315 320  
Gly His Ser Val Ala Val Thr Asp Val Asn Gly Asp Gly Arg His Asp  
325 330 335  
Leu Leu Val Gly Ala Pro Leu Tyr Met Glu Ser Arg Ala Asp Arg Lys  
340 345 350  
Leu Ala Glu Val Gly Arg Val Tyr Leu Phe Leu Gln Pro Arg Gly Pro  
355 360 365  
His Ala Leu Gly Ala Pro Ser Leu Leu Leu Thr Gly Thr Gln Leu Tyr  
370 375 380  
Gly Arg Phe Gly Ser Ala Ile Ala Pro Leu Gly Asp Leu Asp Arg Asp  
385 390 395 400  
Gly Tyr Asn Asp Ile Ala Val Ala Ala Pro Tyr Gly Gly Pro Ser Gly  
405 410 415  
Arg Gly Gln Val Leu Val Phe Leu Gly Gln Ser Glu Gly Leu Arg Ser  
420 425 430

Arg Pro Ser Gln Val Leu Asp Ser Pro Phe Pro Thr Gly Ser Ala Phe  
 435 440 445  
 Gly Phe Ser Leu Arg Gly Ala Val Asp Ile Asp Asp Asn Gly Tyr Pro  
 450 455 460  
 Asp Leu Ile Val Gly Ala Tyr Gly Ala Asn Gln Val Ala Val Tyr Arg  
 465 470 475 480  
 Ala Gln Pro Val Val Lys Ala Ser Val Gln Leu Leu Val Gln Asp Ser  
 485 490 495  
 Leu Asn Pro Ala Val Lys Ser Cys Val Leu Pro Gln Thr Lys Thr Pro  
 500 505 510  
 Val Ser Cys Phe Asn Ile Gln Met Cys Val Gly Ala Thr Gly His Asn  
 515 520 525  
 Ile Pro Gln Lys Leu Ser Leu Asn Ala Glu Leu Gln Leu Asp Arg Gln  
 530 535 540  
 Lys Pro Arg Gln Gly Arg Arg Val Leu Leu Leu Gly Ser Gln Gln Ala  
 545 550 555 560  
 Gly Thr Thr Leu Asn Leu Asp Leu Gly Gly Lys His Ser Pro Ile Cys  
 565 570 575  
 His Thr Thr Met Ala Phe Leu Arg Asp Glu Ala Asp Phe Arg Asp Lys  
 580 585 590  
 Leu Ser Pro Ile Val Leu Ser Leu Asn Val Ser Leu Pro Pro Thr Glu  
 595 600 605  
 Ala Gly Met Ala Pro Ala Val Val Leu His Gly Asp Thr His Val Gln  
 610 615 620  
 Glu Gln Thr Arg Ile Val Leu Asp Ser Gly Glu Asp Asp Val Cys Val  
 625 630 635 640  
 Pro Gln Leu Gln Leu Thr Ala Ser Val Thr Gly Ser Pro Leu Leu Val  
 645 650 655  
 Gly Ala Asp Asn Val Leu Glu Leu Gln Met Asp Ala Ala Asn Glu Gly  
 660 665 670  
 Glu Gly Ala Tyr Glu Ala Glu Leu Ala Val His Leu Pro Gln Gly Ala  
 675 680 685  
 His Tyr Met Arg Ala Leu Ser Asn Val Glu Gly Phe Glu Arg Leu Ile  
 690 695 700  
 Cys Asn Gln Lys Lys Glu Asn Glu Thr Arg Val Val Leu Cys Glu Leu  
 705 710 715 720  
 Gly Asn Pro Met Lys Lys Asn Ala Gln Ile Gly Ile Ala Met Leu Val  
 725 730 735  
 Ser Val Gly Asn Leu Glu Glu Ala Gly Glu Ser Val Ser Phe Gln Leu  
 740 745 750  
 Gln Ile Arg Ser Lys Asn Ser Gln Asn Pro Asn Ser Lys Ile Val Leu  
 755 760 765  
 Leu Asp Val Pro Val Arg Ala Glu Ala Gln Val Glu Leu Arg Gly Asn  
 770 775 780  
 Ser Phe Pro Ala Ser Leu Val Val Ala Ala Glu Glu Gly Glu Arg Glu  
 785 790 795 800  
 Gln Asn Ser Leu Asp Ser Trp Gly Pro Lys Val Glu His Thr Tyr Glu  
 805 810 815  
 Leu His Asn Asn Gly Pro Gly Thr Val Asn Gly Leu His Leu Ser Ile  
 820 825 830  
 His Leu Pro Gly Gln Ser Gln Pro Ser Asp Leu Leu Tyr Ile Leu Asp  
 835 840 845  
 Ile Gln Pro Gln Gly Gly Leu Gln Cys Phe Pro Gln Pro Pro Val Asn  
 850 855 860  
 Pro Leu Lys Val Asp Trp Gly Leu Pro Ile Pro Ser Pro Ser Pro Ile  
 865 870 875 880  
 His Pro Ala His His Lys Arg Asp Arg Arg Gln Ile Phe Leu Pro Glu  
 885 890 895  
 Pro Glu Gln Pro Ser Arg Leu Glu Asp Pro Val Leu Val Ser Cys Asp  
 900 905 910  
 Ser Ala Pro Cys Thr Val Val Gln Cys Asp Leu Gln Glu Met Ala Arg  
 915 920 925  
 Gly Gln Arg Ala Met Val Thr Val Leu Ala Phe Leu Trp Leu Pro Ser



930 935 940  
 Leu Tyr Gln Arg Pro Leu Asp Gln Phe Val Leu Gln Ser His Ala Trp  
 945 950 955 960  
 Phe Asn Val Ser Ser Leu Pro Tyr Ala Val Pro Pro Leu Ser Leu Pro  
 965 970 975  
 Arg Gly Glu Ala Gln Val Trp Thr Gln Leu Leu Arg Ala Leu Glu Glu  
 980 985 990  
 Arg Ala Ile Pro Ile Trp Trp Val Leu Val Gly Val Leu Gly Gly Leu  
 995 1000 1005  
 Leu Leu Leu Thr Ile Leu Val Leu Ala Met Trp Lys Val Gly Phe Phe  
 1010 1015 1020  
 Lys Arg Asn Arg Pro Pro Leu Glu Glu Asp Asp Glu Glu Gly Glu  
 1025 1030 1035  
  
 <210> 8  
 <211> 1039  
 <212> PRT  
 <213> Homo sapiens  
  
 <400> 8  
 Met Ala Arg Ala Leu Cys Pro Leu Gln Ala Leu Trp Leu Leu Glu Trp  
 1 5 10 15  
 Val Leu Leu Leu Leu Gly Pro Cys Ala Ala Pro Pro Ala Trp Ala Leu  
 20 25 30  
 Asn Leu Asp Pro Val Gln Leu Thr Phe Tyr Ala Gly Pro Asn Gly Ser  
 35 40 45  
 Gln Phe Gly Phe Ser Leu Asp Phe His Lys Asp Ser His Gly Arg Val  
 50 55 60  
 Ala Ile Val Val Gly Ala Pro Arg Thr Leu Gly Pro Ser Gln Glu Glu  
 65 70 75 80  
 Thr Gly Gly Val Phe Leu Cys Pro Trp Arg Ala Glu Gly Gly Gln Cys  
 85 90 95  
 Pro Ser Leu Leu Phe Asp Leu Arg Asp Glu Thr Arg Asn Val Gly Ser  
 100 105 110  
 Gln Thr Leu Gln Thr Phe Lys Ala Arg Gln Gly Leu Gly Ala Ser Val  
 115 120 125  
 Val Ser Trp Ser Asp Val Ile Val Ala Cys Ala Pro Trp Gln His Trp  
 130 135 140  
 Asn Val Leu Glu Lys Thr Glu Glu Ala Glu Lys Thr Pro Val Gly Ser  
 145 150 155 160  
 Cys Phe Leu Ala Gln Pro Glu Ser Gly Arg Ala Glu Tyr Ser Pro  
 165 170 175  
 Cys Arg Gly Asn Thr Leu Ser Arg Ile Tyr Val Glu Asn Asp Phe Ser  
 180 185 190  
 Trp Asp Lys Arg Tyr Cys Glu Ala Gly Phe Ser Ser Val Thr Gln  
 195 200 205  
 Ala Gly Glu Leu Val Leu Gly Ala Pro Gly Gly Tyr Tyr Phe Leu Gly  
 210 215 220  
 Leu Leu Ala Gln Ala Pro Val Ala Asp Ile Phe Ser Ser Tyr Arg Pro  
 225 230 235 240  
 Gly Ile Leu Leu Trp His Val Ser Ser Gln Ser Leu Ser Phe Asp Ser  
 245 250 255  
 Ser Asn Pro Glu Tyr Phe Asp Gly Tyr Trp Gly Tyr Ser Val Ala Val  
 260 265 270  
 Gly Glu Phe Asp Gly Asp Leu Asn Thr Thr Glu Tyr Val Val Gly Ala  
 275 280 285  
 Pro Thr Trp Ser Trp Thr Leu Gly Ala Val Glu Ile Leu Asp Ser Tyr  
 290 295 300  
 Tyr Gln Arg Leu His Arg Leu Arg Ala Glu Gln Met Ala Ser Tyr Phe  
 305 310 315 320  
 Gly His Ser Val Ala Val Thr Asp Val Asn Gly Asp Gly Arg His Asp  
 325 330 335  
 Leu Leu Val Gly Ala Pro Leu Tyr Met Glu Ser Arg Ala Asp Arg Lys

340 345 350  
 Leu Ala Glu Val Gly Arg Val Tyr Leu Phe Leu Gln Pro Arg Gly Pro  
 355 360 365  
 His Ala Leu Gly Ala Pro Ser Leu Leu Leu Thr Gly Thr Gln Leu Tyr  
 370 375 380  
 Gly Arg Phe Gly Ser Ala Ile Ala Pro Leu Gly Asp Leu Asp Arg Asp  
 385 390 395 400  
 Gly Tyr Asn Asp Ile Ala Val Ala Ala Pro Tyr Gly Gly Pro Ser Gly  
 405 410 415  
 Arg Gly Gln Val Leu Val Phe Leu Gly Gln Ser Glu Gly Leu Arg Ser  
 420 425 430  
 Arg Pro Ser Gln Val Leu Asp Ser Pro Phe Pro Thr Gly Ser Ala Phe  
 435 440 445  
 Gly Phe Ser Leu Arg Gly Ala Val Asp Ile Asp Asp Asn Gly Tyr Pro  
 450 455 460  
 Asp Leu Ile Val Gly Ala Tyr Gly Ala Asn Gln Val Ala Val Tyr Arg  
 465 470 475 480  
 Ala Gln Pro Val Val Lys Ala Ser Val Gln Leu Leu Val Gln Asp Ser  
 485 490 495  
 Leu Asn Pro Ala Val Lys Ser Cys Val Leu Pro Gln Thr Lys Thr Pro  
 500 505 510  
 Val Ser Cys Phe Asn Ile Gln Met Cys Val Gly Ala Thr Gly His Asn  
 515 520 525  
 Ile Pro Gln Lys Leu Ser Leu Asn Ala Glu Leu Gln Leu Asp Arg Gln  
 530 535 540  
 Lys Pro Arg Gln Gly Arg Arg Val Leu Leu Leu Gly Ser Gln Gln Ala  
 545 550 555 560  
 Gly Thr Thr Leu Asn Leu Asp Leu Gly Gly Lys His Ser Pro Ile Cys  
 565 570 575  
 His Thr Thr Met Ala Phe Leu Arg Asp Glu Ala Asp Phe Arg Asp Lys  
 580 585 590  
 Leu Ser Pro Ile Val Leu Ser Leu Asn Val Ser Leu Pro Pro Thr Glu  
 595 600 605  
 Ala Gly Met Ala Pro Ala Val Leu His Gly Asp Thr His Val Gln  
 610 615 620  
 Glu Gln Thr Arg Ile Val Leu Asp Ser Gly Glu Asp Asp Val Cys Val  
 625 630 635 640  
 Pro Gln Leu Gln Leu Thr Ala Ser Val Thr Gly Ser Pro Leu Leu Val  
 645 650 655  
 Gly Ala Asp Asn Val Leu Glu Leu Gln Met Asp Ala Ala Asn Glu Gly  
 660 665 670  
 Glu Gly Ala Tyr Glu Ala Glu Leu Ala Val His Leu Pro Gln Gly Ala  
 675 680 685  
 His Tyr Met Arg Ala Leu Ser Asn Val Glu Gly Phe Glu Arg Leu Ile  
 690 695 700  
 Cys Asn Gln Lys Lys Glu Asn Glu Thr Arg Val Val Leu Cys Glu Leu  
 705 710 715 720  
 Gly Asn Pro Met Lys Lys Asn Ala Gln Ile Gly Ile Ala Met Leu Val  
 725 730 735  
 Ser Val Gly Asn Leu Glu Glu Ala Gly Glu Ser Val Ser Phe Gln Leu  
 740 745 750  
 Gln Ile Arg Ser Lys Asn Ser Gln Asn Pro Asn Ser Lys Ile Val Leu  
 755 760 765  
 Leu Asp Val Pro Val Arg Ala Glu Ala Gln Val Glu Leu Arg Gly Asn  
 770 775 780  
 Ser Phe Pro Ala Ser Leu Val Val Ala Ala Glu Glu Gly Glu Arg Glu  
 785 790 795 800  
 Gln Asn Ser Leu Asp Ser Trp Gly Pro Lys Val Glu His Thr Tyr Glu  
 805 810 815  
 Leu His Asn Asn Gly Pro Gly Thr Val Asn Gly Leu His Leu Ser Ile  
 820 825 830  
 His Leu Pro Gly Gln Ser Gln Pro Ser Asp Leu Leu Tyr Ile Leu Asp  
 835 840 845

Ile Gln Pro Gln Gly Gly Leu Gln Cys Phe Pro Gln Pro Pro Val Asn  
 850 855 860  
 Pro Leu Lys Val Asp Trp Gly Leu Pro Ser Pro Ser Pro Ser Pro Ile  
 865 870 875 880  
 His Pro Ala His His Lys Arg Asp Arg Arg Gln Ile Phe Leu Pro Glu  
 885 890 895  
 Pro Glu Gln Pro Ser Arg Leu Gln Asp Pro Val Leu Val Ser Cys Asp  
 900 905 910  
 Ser Ala Pro Cys Thr Val Val Gln Cys Asp Leu Gln Glu Met Ala Arg  
 915 920 925  
 Gly Gln Arg Ala Met Val Thr Val Leu Ala Phe Leu Trp Leu Pro Ser  
 930 935 940  
 Leu Tyr Gln Arg Pro Leu Asp Gln Phe Val Leu Gln Ser His Ala Trp  
 945 950 955 960  
 Phe Asn Val Ser Ser Leu Pro Tyr Ala Val Pro Pro Leu Ser Leu Pro  
 965 970 975  
 Arg Gly Glu Ala Gln Val Trp Thr Gln Leu Leu Arg Ala Leu Glu Glu  
 980 985 990  
 Arg Ala Ile Pro Ile Trp Trp Val Leu Val Gly Val Leu Gly Gly Leu  
 995 1000 1005  
 Leu Leu Leu Thr Ile Leu Val Leu Ala Met Trp Lys Val Gly Phe Phe  
 1010 1015 1020  
 Lys Arg Asn Arg Pro Pro Leu Glu Glu Asp Asp Glu Glu Gly Glu  
 1025 1030 1035

<210> 9  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 9  
 agacttcctc ctcagacctc cacct

25

<210> 10  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 10  
 taaactctta gctattggga agtggtta

27

<210> 11  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Synthetic

<400> 11  
 ttctgattgc tggacttctc tt

22

<210> 12  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 12

tctctcccca tggcaaagag t

21

&lt;210&gt; 13

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 13

ctgtcaaccc tctcaaggta a

21

&lt;210&gt; 14

&lt;211&gt; 27

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic

&lt;400&gt; 14

gccgggtgaa tgggggaggg gctggcg

27

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/01696

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 391 714 A (ASTER RICHARD H ET AL) 21 February 1995 (1995-02-21) see whole doc. esp. col.2, line 55 ---	4-6, 11, 12, 14, 16
X	WO 91 08306 A (BLOOD CENTER OF SOUTHEASTERN W) 13 June 1991 (1991-06-13) the whole document ---	4-6, 12, 13, 15, 17
X	US 5 652 357 A (NEWMAN PETER J ET AL) 29 July 1997 (1997-07-29) see whole doc. esp. col.2, line 40 ff. --- -/--	4-6, 15, 17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

23 February 2000

Date of mailing of the international search report

01/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Müller, F

# INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/IB 99/01696

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WEISS E J ET AL: "A MONOCLONAL ANTIBODY (SZ21) SPECIFIC FOR PLATELET GPIIIA DISTINGUISHES P1A1 FROM P1A2" TISSUE ANTIGENS, DK, MUNKSGAARD, COPENHAGEN, vol. 46, 1 January 1995 (1995-01-01), pages 374-381, XP002911947  ISSN: 0001-2815  the whole document</p>	<p>4-6, 14, 16</p>
P, X	<p>US 5 955 266 A (GOLDSCHMIDT-CLERMONT PASCAL J ET AL)  21 September 1999 (1999-09-21)  the whole document</p>	<p>4-6, 14-17</p>

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/01696

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5391714 A	21-02-1995	US 5091302 A	25-02-1992
		US 5670337 A	23-09-1997
		AT 161055 T	15-12-1997
		AU 5551690 A	16-11-1990
		DE 69031804 D	22-01-1998
		DE 69031804 T	02-04-1998
		EP 0477201 A	01-04-1992
		JP 5500599 T	12-02-1993
		WO 9012593 A	01-11-1990
WO 9108306 A	13-06-1991	US 5436163 A	25-07-1995
		AU 6276890 A	26-06-1991
		US 5652357 A	29-07-1997
US 5652357 A	29-07-1997	US 5436163 A	25-07-1995
		AU 6276890 A	26-06-1991
		WO 9108306 A	13-06-1991
US 5955266 A	21-09-1999	NONE	